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Abstract
The genetic basis of schizophrenia is still largely unknown. Recent evidence suggests that
a microRNA (miRNA), miR-137 may be involved. The first large schizophrenia genome
wide association (GWAS) study, published in 2011, identified a variant within the host
gene of this miRNA (MIR-137) as the top association. Since then, further evidence for the
potential influence of this miRNA within the disorder has accumulated. These studies
used a variety of methods from GWAS to neuroimaging. However, few studies have
evaluated the mechanism for the association of the MIR-137 variant, nor how alterations
in the miRNA may have downstream effects on its targets and the function of these
targets within biological pathways. We hypothesized that the target genes of miR-137 are
vi

involved in schizophrenia relevant pathways, such as those affecting neuronal
development and plasticity, and that the MIR-137 risk-associated variant may lead to
altered regulation of such pathways. We predict that variants within the targets of the
miRNA may further alter target regulation.
Here we completed the following three aims to determine the potential impact of
dysregulation by this miRNA in schizophrenia. 1) We characterized the targets of the
miRNA and the pathways over-representing these genes. 2) We determined the
schizophrenia-risk association of these targets within these target enriched pathways. 3)
We evaluated the influence of variants within target genes of an enriched pathway and
the previously associated miR-137 host gene variant on structural gray matter.
Our results suggest that the targets of this miRNA are indeed involved in pathways
relevant to neuronal development and plasticity and thus the development of
schizophrenia. The target genes within these pathways contain variants associated with
schizophrenia that may disrupt regulation by the miRNA. Variants within targets of the
PKA signaling pathway coupled with the MIR-137 variant may influence the
development of gray matter within the occipital, temporal, and parietal lobe.
Overall, our studies further suggest that this miRNA is influential in schizophrenia and
provide a map for future studies to determine the effects of dysregulation by miR-137 in
the disorder.
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1. Introduction
1.1 Overall Significance
Schizophrenia is a severe mental disorder that greatly impacts the quality of life of those
affected. Current medications have debilitating side effects and are ineffective in treating
all associated symptoms. (Rummel-Kluge et al., 2012 and van Os, and Kapur, 2009)
Heritability estimates suggest that the illness is highly heritable; however, the source of
all estimated heritability remains unexplained (Toulopoulou et al., 2010). Attempts to
determine these sources have demonstrated that genetic risk is likely conferred by many
different genes each of modest contribution (Purcell et al., 2009). Revealing these modest
risk contributor genes could uncover new drug targets that may lead to more effective
treatments.
miRNA are a class of noncoding RNA molecules that post-transcriptionally regulate the
expression of genes. Single miRNA molecules have the capacity to regulate the
expression of hundreds of genes. A role for such regulators in the basis of schizophrenia
is compelling given the polygenic evidence for the underlying genetic architecture.
The first large schizophrenia genome wide association study (GWAS) identified a single
nucleotide polymorphism (SNP) within the host gene of miR-137 (MIR-137) as the top
associated variant (Ripke et al., 2011). Subsequent larger GWAS have confirmed an
association with this locus (Ripke et al., 2014). In vitro studies indicate that this miRNA
influences several processes critical for proper neuronal development (Silber et al., 2008;
Smrt et al., 2010; Sun et al., 2011; Szulwach et al., 2010), suggesting that this host gene
variant could affect these functions. Imaging genetics studies show that risk allele carriers
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with schizophrenia have uniquely altered structural and functional MRI measures as
compared to risk allele carriers that are healthy controls (Lett et al., 2013; Whalley et al.,
2012). These findings, in agreement with the polygenic risk evidence (Purcell et al.,
2009), suggest that additional genetic alterations may account for the distinct effect of
this variant in patients. However, the mechanisms responsible for such findings are not
known.
Alterations in genes regulated by miR-137 coupled with dysregulation by this miRNA
may synergistically contribute to schizophrenia risk. Pathways highly enriched with such
genes may be particularly sensitive to enhancement of risk and therefore may reveal the
role of this miRNA in the disorder. Therefore determination of the possible target genes,
pathways enriched with such genes, and the impact of such genes on schizophrenia risk
and imaging measures may be instrumental in discovering the impact of this miRNA and
reveal undiscovered sources of heritability.

1.2 miRNA mediated regulation of gene expression
1.2.1 miRNA evolutionary significance
Despite the fact that non-coding DNA does not code for proteins, non-coding DNA
makes up roughly 98.8% of the human genome (Amaral et al., 2008). Genomic
comparisons across species indicate that the ratio of noncoding DNA to protein coding
DNA is increasingly larger in more complex and higher order species, and humans
appear to have the largest proportion of noncoding DNA (Mattick, 2004). This suggests
that noncoding DNA may be responsible for many of the newly evolved processes and
functions in higher order species and when altered may contribute to the diseases that
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impact these processes. One particular class of noncoding RNA molecules coded by
noncoding DNA, microRNA (miRNA) appears to increase with greater species
complexity (Sempere et al., 2006). In fact many miRNAs were identified to be primate
specific (Bentwich et al., 2005) and an estimated 1% of brain expressed miRNAs were
found to be unique to humans when comparing chimps and humans (Wienholds, 2005).
Furthermore expression and functional differences of even well conserved miRNAs
across species has been identified, suggesting that specific manipulations of these
molecules may in part drive the evolution of more complex functions in higher order
organisms. (Ason et al., 2006; Niwa and Slack, 2007) Given that miRNA play a critical
role in fine tuning higher complexity processes, alterations in their function may lead to
disease states in which these processes are impaired.

1.2.2 miRNA biogenesis and post-transcriptional regulation
Discovered in 1993 in Caenorhabditis elegans (Lee et al., 1993), miRNAs are a small
noncoding RNA molecules of approximately 22 nucleotides in length that posttranscriptionally regulate the expression of specific genes (Bartel and Chen, 2004).
Individual miRNA molecules specify genes for regulation through complimentary
binding of miRNAs to respective mRNA molecules (Bartel, 2009). miRNA influence and
control a variety of processes, from controlling developmental gene expression in C.
elegans (Lee et al., 1993), to rapid cellular response of environmental stimuli in neuronal
plasticity (Olde Loohuis et al., 2012). Alterations in miRNA function are associated with
a variety of diseases from cardiovascular illness, to neurodegenerative disorders, to
cancer (Ruepp et al., 2010).

3

miRNAs are first transcribed in the nucleus, generally by RNA polymerase II, either from
non-coding regions of the genome or less commonly within an intron of a protein coding
gene. These latter transcripts of a less common origin termed mirtrons skip the first step
of miRNA biogenesis, namely the processing of the primary transcript. Primary or primiRNAs, are cleaved within the nucleus by an enzyme complex called the
microprocessor which contains the RNAse III enzyme Drosha and targeting protein
DiGeorge syndrome critical region gene 8 (DCGR8). This processing leads to production
of the secondary stage for these transcripts called pre-miRNA. In contrast, mirtrons are
spliced out like a regular intron to form the pre-miRNA (Guo and Lu, 2010; Huang et al.,
2014; Lin et al., 2006; Schwarz et al., 2003). At this stage, the transcript is exported to
the cytoplasm via Exportin-5 for further processing to reach a final stage of maturity. In
the cytoplasm these pre-miRNAs are targeted by a protein complex containing Dicer, the
trans-activation response RNA binding protein (TRBP), and the protein activator of the
interferon induced protein kinase (PACT). This protein complex cleaves the terminal
loop of the pre-miRNA to produce a double stranded short RNA sequence. Either of
these strands can act as the mature miRNA for subsequent post-transcriptional regulation
and target different genes for regulation, but generally one strand is more commonly
active. This phenomenon of strand bias is called strand asymmetry. Usually the strand
with the least thermodynamically stable 5’end, most often derived from the 5’ arm of the
pre-miRNA stem loop, serves as the guide strand to guide mRNA silencing. The other
strand called the passenger strand is later degraded. (Guo and Lu, 2010; Huang et al.,
2014; Schwarz et al., 2003) The mature strand is taken up and bound by the microRNA
induced Silencing Complex (miRISC) containing Argonaute 2 (Ago 2), which has

4

endonuclease activity and used by the complex to target complementary mRNA
sequences and to repress subsequent protein expression. (Carthew and Sontheimer, 2009;
Cuperus et al., 2011; Lindow and Gorodkin, 2007) In most instances, miRNAs lead to a
reduction or silencing of subsequent protein expression, either via translational repression
or mRNA degradation (Carthew and Sontheimer, 2009; Filipowicz et al., 2008).

1.2.3 Interactions of miRNA and mRNA
miRNAs target mRNAs by binding to small sequences generally located in the 3’ UTR of
the mRNA. However, some miRNA target sequences located within the 5’ UTR or
coding sequence of a mRNA. The cognate miRNA binding sequence is referred to as the
seed and most often consists of the first 2-8 nucleotides of the 5’ UTR. (Filipowicz et al.,
2008) These seed sequences within miRNA often perfectly match their cognate mRNA
sequences. These cognate mRNA sequences appear to have had evolutionary pressure to
be maintained and are often found to be conserved across many species. Other seed sites
however appear to be recently evolved. Sequences adjacent to the seed-binding site or
elsewhere in the 3’UTR of a miRNA called 3’-supplementary sites and 3’-compensatory
sites may help to stabilize binding or compensate for imperfect seed binding respectively
(Bartel, 2009). Research suggests that an adenine at position 1 of the targeted mRNA
sequence may be involved in recognition of mRNA targets by the miRISC.
Multiple types of seed pairing sequences have been observed. The canonical or more
frequently observed pairing consists of bound sequences of 7-8 nucleotides in length
between the miRNA seed and the mRNA, as well as frequent pairing between the mRNA
and the first nucleotide of the miRNA or the nucleotide directly after the seed sequence in
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position 8. Less frequently, nucleotide parings of only 6 nucleotides in length or those of
imperfect seed pairing with 3’-compensatory site pairings have been observed.(Bartel,
2009)
miRNA targets can be predicted using computer based algorithms or determined using
experimental validation studies. A variety of miRNA target prediction algorithms are
available with varied requirements based on seed site complementarity, binding
thermodynamic stability, surrounding sequences, and conservation. Different algorithms
also investigate different mRNA regions; some only evaluate the 3’UTR while others
evaluate 5’UTRS and coding regions. (Lindow and Gorodkin, 2007) Experimental
validation studies often examine the expression of potential targets in response to the
miRNA of interest. New methods such as those of transcriptomics include: microarray
profiling to test target level expression following transfection of miRNAs in cellular
assays, RNA sequencing to detect changes in mRNA levels, high-throughput sequencing
of RNA isolated by crosslinking immunopercipitation (HITS-CLIP) to find miRNAmRNA-Ago complexes, and many more rapidly developing methods. In vitro assays
include luciferase assays using transfections of plasmids containing the luciferase coding
region with the 3’ UTR of predicted targets along with precursors for the miRNA. In
addition, studies using western blots of protein products of predicted targets, and animal
studies of miRNA knockouts and over-expression are used to study the effect of specific
miRNAs. Current annotations of experimentally validated targets are not very extensive,
but with advancing target detection methodologies these annotations will soon be much
more extensive. (Tarang and Weston, 2014)
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1.2.4 Summary
miRNA are a class of noncoding RNAs that regulate the expression of specific genes.
Each individual miRNA has the capacity to target hundreds of genes and thus can have
great impact on a variety of biological processes. miRNA regulation alterations also
appear to play a major role in a variety of diseases.

1.3 miRNA alterations in disease
Alterations in miRNA mediated gene regulation has been linked to nearly every variety
of disease (Ruepp et al., 2010) including schizophrenia. These alterations may affect the
biogenesis or function of the miRNA, or affect targeting of the miRNA to its respective
targets (Sun et al., 2009). The following sections review current literature about miRNA
alterations in phenotypes and diseases.

1.3.1 miRNA alterations
SNPs and copy number variations (CNVs) located within miRNA host genes or their
regulatory regions can impact miRNA biogenesis and function and lead to subsequent
alterations affecting phenotypes and diseases (Duan et al., 2009). There are several
vulnerabilities associated with miRNA biogenesis that can be affected by SNPs and
CNVs. Like protein coding genes, miRNA host gene transcription is regulated by a
transcription factors, activators, or epigenetic alterations and accordingly any variant
impacting regulation of transcription could have consequences on miRNA expression
(Filipowicz et al., 2008; Slezak-Prochazka et al., 2010). miRNA biogenesis is often
regulated by negative feedback loops either through auto-regulation by a miRNA itself or
through double negative feedback loops by specific miRNA targets (Li and Carthew,
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2005). Therefore, SNPs or CNVs affecting the expression of a miRNA may have
compounding consequences if the miRNA is self-regulating. Variants affecting the
expression of regulatory target genes may also effect miRNA expression and thus may
influence regulation of other target genes. Processing of the miRNA is also vulnerable to
genetic variation. Terminal loop binding proteins, such as KSRP or Lin28 can inhibit or
facilitate the actions of miRNA processing enzymes, Dicer and Drosha. Alterations in the
pri-miRNA or pre-miRNA sequences can alter the binding of these loop binding proteins.
(Filipowicz et al., 2008; Slezak-Prochazka et al., 2010). Variants in these sequences can
also alter the way in which Dicer and Drosha cleave these premature miRNAs. This can
lead to a shifted or altered seed sequence, alter which of the two strands is loaded into the
miRISC complex, or change the processing rate by potentially altering premature miRNA
stability (Sun et al., 2009) thus impacting regulation. Alterations in pri-miRNA and premiRNA sequences that are otherwise harmless could also theoretically lead to adenosine
deaminase acting on RNA (ADAR) modifications that then subsequently lead to a shift in
the seed sequences (Kawahara et al., 2007; Luciano, 2004)
Most examples of SNPs and CNVs impacting miRNA biogenesis and function have been
best demonstrated so far in Cancer. One such example found a SNP associated with
reduced lung cancer survival that caused a significant increase in the mature form of
miR-196a2, but no alteration in the premature miRNA levels (Hu et al., 2008).
Interestingly, the same genotype for the same SNP also appears to increase risk of
congenital heart disease and increase levels of the mature form of miR-196a2 in cardiac
tissue (Xu, et al., 2009). A few studies outside of cancer have also examined miRNA
SNP consequences. One study identified ultra-rare variants associated with schizophrenia
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that also appear to alter the biogenesis and function of a several miRNAs (Feng et al.,
2009).

1.3.2 Target gene alterations
SNPs and CNVs altering miRNA target genes can also have impact on miRNA induced
regulation. Due to the double-negative feedback loop between target genes and respective
miRNAs, any expression changes in target genes through a variety of mechanisms (such
as activators, repressors etc.) could affect the biogenesis of cognate miRNAs and
secondarily cause downstream changes on additional target gene expression. Variants
within target genes can also alter the targeting of miRNAs by altering target binding.
There are a few cases where such a variant is associated with disease. One example
includes a polymorphism in the seed site of the serotonin receptor 1B mRNA that
disrupts regulation by miR-96 by reducing binding by the miRNA. This polymorphism is
associated with conduct disorder phenotypes in humans (Jensen et al., 2008). It is also
possible for variants to create new target genes by increasing the potential for miRNA
binding. Such novel target genes created by SNPs have been associated with obesity
related phenotypes (Richardson et al., 2011) and plasma triglyceride levels (Caussy et al.,
2014).
1.3.2.1 Consequences of variants in seed site sequences
Clearly sequence changes within a target gene “seed site” in the region that binds to the
seed of miRNA, could alter binding by the miRNA. The sequence alterations can either
increase or decrease binding. There are two known cases of such alterations impacting
diseases of the nervous system. A de novo chromosome 13 inversion associated with
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Tourette’s syndrome was found to cause a frameshift mutation in the binding sequence of
SLITRK1 and increases binding strength for miR-189 (Abelson, 2005).A SNP identified
as a risk factor for Parkinson’s disease disrupts the miR-433 binding site within the target
gene FGF20 and decreases binding. FGF20 expression was found to be increased with
the risk genotype for this SNP (Wang et al., 2008).
1.3.2.2 Consequences of variants in 3’ UTRs
Variants within 3’UTRs but outside of seed site sequences have been associated with
phenotypes and diseases. A polymorphism near but not within the binding site for miR24 within the target gene DHFR reduced repression of this target gene by the miRNA.
The authors speculate that perhaps binding by the miRISC complex may be disrupted by
this SNP and thereby reduce miRNA induced repression. (Mishra et al., 2007) It is also
possible that SNPs within the 3’ UTR but outside of the seed site of target mRNAs may
alter binding availability of the mRNA by the miRNA due to secondary structure
alterations of the mRNA (Day et al., 2014; Haas et al., 2012). Evidence suggests that
polymorphisms associated with chronic Achilles tendinopathy and located within the
3’UTR of the miR-608 target COL5A1 alter the secondary structure of the target mRNA
3’ UTR and thus may disrupt binding availability of the miRNA (Abrahams et al., 2013).

1.3.3 Summary
Variants can impact miRNA biogenesis, function, and targeting and individual examples
have linked such variants to diseases and phenotypes. Variants may occur within miRNA
host genes or within the targets of a miRNA. More specific examples of such variants
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impacting diseases and phenotypes are likely to be identified soon. Alterations in
miRNAs and their target genes may occur in schizophrenia.

1.4 Schizophrenia
1.4.1 Incidence and impact
Every year, roughly 15 out of 100,000 individuals develops schizophrenia. The average
point prevalence of the disorder is 4.5 people out of every 1000. Lifetime risk for the
development of the illness ranges from 0.3 to 2% and this risk is increased with urban
childhood environment, migration, early social stress, maternal infection, cannabis use,
early life infection, vitamin D deficiency, and male gender among other factors. The
incidence of schizophrenia appears to be stable over time and appears to be neither
increasing nor decreasing. (Tandon et al., 2008)
More than two-thirds of all cases are sporadic, meaning that most individuals are the first
in their family to develop the disorder. However, familial prevalence greatly increases the
risk of development. Monozygotic twin studies indicate that the risk of schizophrenia
development is about 50% for a currently unaffected twin when the other is diagnosed.
This risk is10-15% for non-twin siblings. (Tandon et al., 2008) These studies also provide
measurements for heritability. Heritability of a disease is a measure of the proportion of
disease risk that is due to genetic effects, either directly or indirectly through
environmental interaction. The heritability of schizophrenia is estimated to be 81%
(Sullivan PF, 2003). The genetic sources of such heritability remains largely unknown
(van Os and Kapur, 2009).
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Schizophrenia greatly impacts the wellbeing of those diagnosed, as well as caregivers and
family (Hanzawa et al., 2013). Unfortunately current treatments are only partially
effective (Blanchard et al., 2011) and are often associated with challenging side effects
(Rummel-Kluge et al., 2012). Schizophrenia remains one of the costliest mental disorders
and leads to additional secondary health detriments and early mortality of 12-15 years
earlier than the average population, (Thornicroft et al., 2004 and van Os, and Kapur,
2009). Patients are largely unable to work, are limited in major daily activities, and have
overall lower quality of life (Thornicroft et al., 2004). Lifetime suicide risk is 4.9% in
patients (Palmer et al., 2005), which is significantly higher than the average population.
This rate appears to have increased since the 1970s, although it may be more recently
declining (Bushe et al., 2010). Overall schizophrenia is a very severe disorder with
widespread detrimental impact.

1.4.2 Symptoms and onset
Schizophrenia has been described similarly as it is today for about one century (Tandon
et al., 2008). Bleuler coined the term schizophrenia in 1911 to describe the “split-mind”
like state of those affected (Moskowitz and Heim, 2011). Schizophrenia is a form of
psychosis; however, there are many other forms of psychosis that differ from the illness
in various ways. The illness is described by three types of symptoms: negative, positive,
and cognitive. The negative symptoms refer to reduced motivation, reduced sociability,
and decreased expressivity and speech. Positive symptoms are characterized by delusion
and hallucinations. Cognitive symptoms often include memory impairment, executive
functioning impairment and alterations in attention. (van Os and Kapur, 2009) Unlike
other forms of psychosis, affective symptoms are generally less severe. Onset of the
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illness typically occurs in early adulthood, although it can occur in childhood or late in
life. Onset in males is often earlier than in females (Godar and Bortolato, 2014).

1.4.3 Genetic architecture
Determination of the genetic contributors underlying schizophrenia risk has been
challenging due to several limiting factors. Diagnostic criteria are still evolving and show
an overlap with several disorders, suggesting that some genetic mechanisms may be
common to a particular symptom-type rather than disease. Indeed, risk loci identified in
GWAS studies that may affect calcium signaling are common to autism spectrum
disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive
disorder, and schizophrenia (Smoller et al., 2013). On the other hand, the heterogeneous
presentation of symptoms in different subjects suggests that there may actually be several
distinct forms of schizophrenia and each may have a unique genetic basis. It is possible
that there are some shared underlying genetic commonalties across disorders that
associate with a particular symptom-type and that predispose for development of a host
of disorders, while other genetic causative factors may be specific to each disorder
(Bertolino and Blasi, 2009). This suggests that studies to determine both types of genetic
factors will be helpful.
To further complicate the search for the underlying genetic basis of schizophrenia,
association studies suggests that the underlying architecture is highly polygenic,
heterogeneous and muddled with environmental interactions, incomplete penetrance,
epistasis, and pleiotropy (Bertolino and Blasi, 2009). In other words, it appears that genes
may have different effects in different subjects, that many genes are playing a role, and
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that these genes are interacting with one another and the environment. Consequently, the
potential for a role of a miRNA, which clearly interact with many genes and respond
quickly to environmental factors, in schizophrenia seems highly probable.
Common and rare variants both appear to play a role in schizophrenia (Sullivan et al.,
2012). Given the potential for variants to disrupt miRNA regulation and have many
downstream effects in multiple systems and pathways it is compelling to suggest that
such alterations may occur in the underlying genetic basis of schizophrenia.

1.4.4 Summary
The genetic architecture of schizophrenia is very complex. Many genes appear to be
involved and may have many interactive genetic and environmental partners. Further
GWAS are necessary to examine the genetic basis of psychiatric symptom dimensions as
a continuum across disorders, as well as those evaluating schizophrenia subtypes to tease
out the genetic factors that are common and unique to specific subject groups.

1.5 miR-137 and schizophrenia
More and more studies are elucidating an important role for miRNA in psychiatric illness
and schizophrenia. miRNAs are found to be differentially expressed in postmortem tissue
and plasma of schizophrenia patients (Beveridge et al., 2009; Gardiner et al., 2011; Kim
et al., 2010; Lai et al., 2011; Perkins et al., 2007; Santarelli et al., 2011). A deletion in
chromosome 22, 22q11.2, is the strongest genetic factor for schizophrenia risk (Forstner
et al., 2013). This deletion encompasses the DGCR8, of the microprocessor complex. A
subsequent decrease in miRNA biogenesis may be responsible for the link between the
deletion and schizophrenia risk. (Forstner et al., 2013). Alterations in the miRNA
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processing protein Dicer and its gene DICER1 are also associated with schizophrenia
(Sanders et al., 2013) further suggesting that miRNA biogenesis may be altered in
schizophrenia. Of all miRNA, miR-137 has an especially large level of evidence for
involvement in the nervous system and its possible influence in schizophrenia. The
following sections review the current evidence for the potential impact of miR-137 in
schizophrenia.

1.5.1 miR-137 functional studies
miR-137 is expressed in brain tissue (Guella et al., 2013; Smrt et al., 2010; Sun et al.,
2011) and localized to synaptosomes (Siegel et al., 2009). The miRNA appears to
regulate neurogenesis and dendritic spine morphogenesis. Over-expression and
antagonism studies suggest that a particular level of miR-137 expression is necessary for
proper control of neuronal proliferation and differentiation of newborn neurons, in the
hippocampus. development ( Silber et al., 2008; Smrt et al., 2010; Sun et al., 2011;
Szulwach et al., 2010).
More recent studies have evaluated the functional role of the miRNA in the nervous
system in a more pathway driven manner. One such study examined RNA expression
changes following miR-137 over-expression and inhibition within a human neural
progenitor cell line and found an overrepresentation of these genes in the neuronal
differentiation pathway (Hill et al., 2014). These results confirm previous findings
implicating a role for this miRNA in neurogenesis. Another similar study also evaluated
pathways enriched with genes of altered expression following miR-137 over-expression
in human neuronal stem cells. Apparent targets enriched pathways including those
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involved with the major histocompatibility complex (MHC), synapse formation, and
calcium channel signaling (Collins et al., 2014).
All of the above implicated pathways are relevant to schizophrenia. Neurogenesis is
linked with cognition (Couillard-Despres et al., 2011). Consequently, neurogenesis
alterations may mechanistically underlie the cognitive deficits associated with the
disorder (O’Reilly et al., 2014; Toro and Deakin, 2007). Synapse formation (Yang et al.,
2014), calcium signaling (Mukherjee et al., 2014 and Berridge, 2013), and the MHC
(Mukherjee et al., 2014) have all been previously associated with schizophrenia. Overall,
the functional studies of miR-137 demonstrate that the miRNA is an important regulator
of the nervous system and may be involved in mechanisms expected to be altered in
schizophrenia.

1.5.2 Genetic variant evidence
The first large scale schizophrenia GWAS identified 5 new common SNPs associated
with the disorder (Ripke et al., 2011). This study utilized genotypic data from over
50,000 subjects all of European Ancestry. The top newly associated SNP was located in
an intron of the host gene for miR-137. The other four newly associated SNPs were
located in genes that are now verified targets of the miRNA including: CSMD1,
C10orf26, CACNA1C, and TCF4 (Kwon et al., 2013). An analysis with 3,000 Han
Chinese subjects confirmed schizophrenia-association of this miR-137 host gene SNP
and the top SNPs from the CACNA1C gene (Guan et al., 2013). This further suggests
that these SNPs may indeed play a role in the illness. Combining the data of this first
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large scale GWAS with additional subjects, another SNP located near the miR-137 host
gene was identified to be newly associated with the disease as well (Ripke et al., 2013).
A recent study identified two variants in the miR-137 host gene that occurred in higher
frequency in patients with schizophrenia or bipolar disorder than controls in a cohort
including just over 2,000 subjects. These variants reduced expression of the mature
miRNA in a neuronal-like cell line (SH-SY5Y). Transcriptome analysis demonstrated
that the reduced miR-137 expression disrupted regulation of many genes. Gene set
enrichment analysis of these genes revealed that many of these deregulated genes are
involved in glutamate signaling and synaptogenesis, particularly those of the
protocadherin family. (Strazisar et al., 2014) Unfortunately this study did not analyze the
effect of the GWAS implicated SNPs (Ripke et al., 2013, 2011) on miRNA expression,
however it is possible that these SNPs may be merely tagging other variants that impact
miR-137 biogenesis. One post mortem tissue study has however analyzed the influence
of the first large GWAS identified miR-137 SNP (rs1625579) genotype on expression of
the miRNA. This small study found a non-significant decrease in miR-137 expression
within the dorsolateral prefrontal cortex (DLPFC) in both patient and control risk allele
carriers and a significant decrease when evaluating controls only. Interestingly,
expression of the target gene TCF4 appeared to be increased in risk allele carriers. (I.
Guella et al., 2013).

1.5.3 Imaging genetics evidence
Many studies have evaluated the impact of the rs1625579 miR-137 host gene variant on
imaging measures with varied results. In Lett et al., 2013, schizophrenia patients who
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were carriers of the risk allele were found to have reduced white matter integrity, reduced
hippocampal volume and increased lateral ventricle volume measures. No significant
structural difference was identified between control subjects and schizophrenia subjects
who were not carriers of the risk allele. These findings suggest that the impact of the risk
SNP may be distinct in patients. This is in agreement with another study that analyzed
only healthy subjects and found no effect of the genotype on white matter integrity
measures of whole-brain fractional anisotropy or mean diffusivity (Kelly et al., 2014).
Also suggestive of the genotype having a schizophrenia distinct effect, recent work in our
lab demonstrates that the risk allele is associated with significantly increased midposterior corpus callosum volume in patients while trending toward a decrease in control
carriers (Patel et al., unpublished observation). A functional magnetic resonance study
(fMRI) also found distinct genotype effects on schizophrenia at risk subjects as compared
to bipolar at risk subjects and healthy controls. Schizophrenia at risk subjects who were
carriers of the risk allele showed increased activation of the amygdala and pre- and postcentral gyrus during a sentence completion task as compared to non-carriers, while
controls showed the opposite genotypic effect on activation. The bipolar at risk subjects
had a control-like genotypic effect in the amygdala but no genotypic effect in the pre and
post central gyrus. (Whalley et al., 2012) This further suggests that the risk genotype has
specific effects in schizophrenia.
Other findings suggest that some effects of the genotype may be common to both
schizophrenia and healthy control subjects. Within the Whalley et al., 2012 study, a main
effect of genotype was identified across the three diagnostic groups, as greater activation
during the sentence completion task was found in the posterior right medial frontal gyrus
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in non-homozygotes of the risk allele (Whalley et al., 2012). In another fMRI study,
higher (DLPFC) activation during the Sternberg Item Response Paradigm memory task
was found in both control and patient risk allele carriers, though there was no genotypic
effect on task performance. (van Erp et al., 2014) Hyperactivation of this region during
working memory tasks is consistently found in schizophrenia and so the risk genotype
may in part genetically underlie this associated phenotype. Healthy controls who were
also risk allele homozygotes had significantly increased functional connectivity between
the right amygdala and the cingulate gyrus and the right inferior frontal gyrus during a
facial processing task (Mothersill et al., 2014). In this study, the healthy subjects who
were homozygotes did not show increased activity in the amygdala, as was shown by
Whalley et al., 2012, where only the schizophrenia homozygotes demonstrated increased
activation. The extent to which the risk genotype alters connectivity in patients has not
yet been examined. It is possible that connectivity is increased due to a common
genotype effect in patients and controls and additional increased amygdala activity in
homozygous patients may be due to a schizophrenia specific genotype effect. Finally, a
resting state fMRI study on 290 healthy subjects found a genotype effect on DLPFC and
hippocampal formation connectivity and working memory performance prediction (Liu et
al., 2014).This has not been studied in schizophrenia patients so it is unclear if this
genotypic effect is common to both or if there is more of an impact in patients. Further
studies are required to determine the impact of this genotype on structure and functional
measures. No studies have yet analyzed the impact of target SNPs in addition to the
genotype on imaging measures.
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1.5.4 Summary
Increasing evidence suggests that miRNAs are involved in psychiatric illness and
schizophrenia. There is substantial evidence that miR-137 in particular may be involved,
from functional in vitro studies, to genetic association studies, to imaging genetics
studies. This warrants further examination as to the role of this miRNA and its targets in
schizophrenia.
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2. Rationale, Hypothesis, and Specific Aims
2.1 Research rationale
The genetic basis of schizophrenia is largely unknown and current treatments are largely
inadequate in treating negative and cognitive symptoms. Increased understanding for the
genetic basis may allow for the discovery of more effective treatments. The first large
schizophrenia GWAS with a large number of participants, identified a SNP within the
host gene of miR-137 (Ripke et al., 2011). Studies suggest that proper miRNA expression
is critical for many neurodevelopmental processes(Guella et al., 2013; Smrt et al., 2010;
Sun et al., 2011). Imaging genetics studies of the identified host gene variant found
alterations in structural and functional MRI measures (van Erp et al., 2013; Lett et al.,
2013; Whalley et al., 2012). Postmortem tissue analysis suggests that expression of the
miRNA may be altered in carriers of the risk variant (Guella et al., 2013). miRNAs have
the capacity to regulate the expression of hundreds of genes. (Bartel, 2009). Thus,
miRNAs have the potential to play extensive roles in polygenic disorders, and
schizophrenia is a polygenic disorder (Purcell et al., 2009).
Given the functional role of the miRNA, the findings in the studies of the implicated
variant, and the compelling capacity for miRNA regulation alterations in polygenic
disorders, evaluation for the role for miR-137 in schizophrenia is warranted. Only limited
studies have analyzed the impact of the target genes of this miRNA in schizophrenia.
Disease associations with dysregulated miRNA-mRNA interactions due to target gene
polymorphisms have been identified (Jensen et al., 2008; Richardson et al., 2011; Wang
et al., 2008). Pathways highly enriched with miR-137 targets may be especially
vulnerable to dysregulation by the miRNA as multiple genes tightly linked in cascading
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functions may be disrupted. Evaluation of such pathways may assist in uncovering the
biological mechanism for the risk association of the implicated MIR137 variant and
eventually assist in uncovering new drug targets.

2.2 Hypothesis
miR-137 target genes play a role in the pathophysiology of schizophrenia by disrupting
target enriched pathways involved in neuronal development and plasticity.

2.3 Specific aims
2.3.1 Specific aim 1
Characterize through bioinformatics the putative and validated miR-137 target genes and
the potential significance of these genes in schizophrenia:
1) Determine the putative and experimentally validated target genes of miR-137 and
evaluate for inclusion of schizophrenia-associated genes
2) Evaluate and compare the distribution of miR-137 target genes across the genome to
genomic regions with schizophrenia associated CNVs.
3) Evaluate the temporal expression pattern for miR-137 target genes to determine if such
genes have a unique expression pattern that might mirror time points of development,
schizophrenia onset, or deterioration.
4) Evaluate target genes using ingenuity pathway analysis (IPA) for significant canonical
pathways and networks to determine the possible impact that these targets if regulation
by miR-137 was altered.
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2.3.2 Specific aim 2
Evaluate miR-137 target gene contribution to schizophrenia risk:
1) Determine schizophrenia-risk association for lists of predicted and validated target
2) Determine schizophrenia-risk association of pathway-specific target gene sets for
pathways vulnerable to dysregulation by miR-137

2.3.3 Specific aim 3
Evaluate miR-137 target gene contribution to structural gray matter alterations in
schizophrenia:
1) Determine effects of risk associated polymorphisms within target genes on structural
gray matter
2) Evaluate interaction effects of the MIR137 variant and target gene variant on structural
gray matter
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3.1 Abstract
The significant impact of microRNAs (miRNAs) on disease pathology is becoming
increasingly evident. These small non-coding RNAs have the ability to posttranscriptionally silence the expression of thousands of genes. Therefore, dysregulation of
even a single miRNA could confer a large polygenic effect. Schizophrenia is a
genetically complex illness thought to involve multiple genes each contributing a small
risk. Large genome-wide association studies identified miR-137, a miRNA shown to be
involved in neuronal maturation, as one of the top risk genes. To assess the potential
mechanism of impact of miR-137 in this disorder and identify its targets, we used a
combination of literature searches, Ingenuity Pathway Analysis (IPA), and freely
accessible bioinformatics resources. Using TargetScan and the Schizophrenia Gene
Resource (SZGR) database, we found that in addition to CSMD1, C10orf26, CACNA1C,
TCF4, and ZNF804A, five schizophrenia risk genes whose transcripts are also validated
miR-137 targets, there are other schizophrenia-associated genes that may be targets of
miR-137, including ERBB4, GABRA1, GRIN2A, GRM5, GSK3B, NRG2 and HTR2C.
IPA analyses of all the potential targets identified several nervous system functions as the
top canonical pathways including synaptic long-term potentiation, a process implicated in
learning and memory mechanisms and recently shown to be altered in patients with
schizophrenia. Among the subset of targets involved in nervous system development and
function, the top scoring pathways were Ephrin receptor signaling and axonal guidance,
processes that are critical for proper circuitry formation and were shown to be disrupted
in schizophrenia. These results suggest that miR-137 may indeed play a substantial role
in the genetic etiology of schizophrenia by regulating networks involved in neural
development and brain function.
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3.2 Introduction
First discovered in C. elegans (Ruvkun et al., 2004), miRNAs are small noncoding RNA
sequences that play a significant role in the regulation of gene expression, particularly at
the post-transcriptional level. Regulation by miRNAs is a complex process, in which
some miRNAs are capable of targeting and repressing hundreds to even thousands of
transcripts (Selbach et al., 2008). Additionally, many mRNAs are targeted by several
miRNAs (Hu et al., 2008; Selbach et al., 2008). It is estimated that the expression of at
least 30% of human genes are regulated by miRNAs (Lewis et al., 2005; Selbach et al.,
2008). With such high levels of potential regulatory influence, some miRNAs may have
enormous impact on gene expression and such an impact may play a role in the
pathophysiology or etiology of diseases with an elusive genetic basis, such as
schizophrenia. This disease is genetically complex and very little is understood about its
genetic basis or underlying mechanisms (Hamshere et al., 2012). Several recent lines of
research suggest that miRNAs may be involved. First, the gene encoding the DiGeorge
syndrome critical region gene 8 protein (DGCR8), one of the components of the nuclear
miRNA processing complex, is located in a chromosomal location (22q11.2) associated
with high risk for schizophrenia (Stone et al., 2008). Also, a SNP in the gene for a
particular miRNA, miR-137 was found to be one of the common alleles associated with
schizophrenia (Kwon et al., 2013; Ripke et al., 2011). This review examines the role of
this miRNA in brain development and function and explores the potential functional
impact of its known and putative targets on schizophrenia. By identifying the putative
and validated miR-137 targets, and examining their potential contribution to functional
networks, we hope to shed more light on the possible role of this miRNA in the etiology
of the disease.
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3.2.1 microRNA
microRNAs (miRNAs) are small non-coding RNAs with the ability to silence the
expression of multiple target genes by binding to specific sequences of mRNAs. A single
miRNA can impact hundreds to thousands of targets and can affect pathways controlling
a large variety of processes, from normal development to oncogenesis. Pairing is
primarily based on sequence complementarity of a “seed” sequence within the miRNA to
a binding site of the mRNA, generally in the 3’ UTR of the mRNA being suppressed
(Bartel, 2009). The mechanisms by which miRNAs suppress gene expression are still not
well elucidated; however mRNA destabilization and translational repression have been
demonstrated as dominant methods of repressing subsequent protein expression (Carthew
and Sontheimer, 2009).
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Figure 3.1 MicroRNA biogenesis and function. MicroRNAs (miRNA) are generated via the mirtron or
canonical pathway. Primary microRNA (pri-miRNA) from the canonical pathway is further processed by
the Drosha-DGCR8 complex into precursor miRNA (pre-miRNA). Pre-miRNAs derived from both
pathways are then exported from the nucleus by exportin 5. In the cytoplasm, this pre-miRNA is further
processed by the Dicer/TRBP/PACT complex into a duplex miRNA. One of the strands (guide strand or
mature miRNA) is then loaded into the miRISC complex along with the target mRNA. Depending on the
degree of sequence complementary, miRNAs lead to translational repression, deadenylation or degradation
of the target mRNAs, all reducing downstream protein expression. Adenosine deaminases acting on RNA
(ADARs) may inhibit various steps of miRNA processing thus reducing or shifting miRNA function. See
text for more detail.

As shown in Figure 3.1, miRNAs are either first transcribed in the nucleus as primary
miRNAs (pri-miRNAs) or less commonly spliced from introns (Lin et al., 2006). The
pri-miRNAs are then processed in the nucleus by the microprocessor complex involving
the RNAse III enzyme Drosha complexed with the targeting protein DGCR8 into
approximately 89 nucleotide long sequences termed pre-miRNAs (Carthew and

28

Sontheimer, 2009; Cuperus et al., 2011; Lindow and Gorodkin, 2007). Intron derived
miRNAs termed mirtrons are excised by the RNA spliceosomal components and do not
require further processing. These pre-miRNAs are then exported out of the nucleus by
Exportin5 (Lindow and Gorodkin, 2007) and further processed in the cytoplasm by a
protein complex containing Dicer and its associated proteins the trans-activation response
RNA binding protein (TRBP) and the protein activator of the interferon induced protein
kinase (PACT) into an approximately 22 nucleotide long double stranded RNA (Carthew
and Sontheimer, 2009). These double stranded sequences then separate and a single
strand termed guide strand (mature miRNA) is loaded with a complementary mRNA into
an Argonaute containing microRNA-induced silencing complex (miRISC) where the
miRNA ultimately binds the target sequence (Carthew and Sontheimer, 2009) to repress
ensuing protein expression.
Adenosine deaminases acting on RNA (ADARs) can also modify and regulate miRNA
function, both in the nucleus and cytoplasm (Figure 3.1). Adenosine deaminases can
modify miRNA processing and function not only by editing pri- and pre-miRNA
sequences but also through steric hindrance in the absence of RNA editing (Heale et al.,
2009). Alterations in miRNA sequence can lead to shifted (Kawahara et al., 2007),
reduced, or eliminated targeting or reduction in mature miRNA production(Luciano,
2004). ADAR miRNA editing seems to play an important role in mammalian brain
development (Ekdahl et al., 2012). Surprisingly, very few studies have addressed the
potential role of ADAR mRNA editing in psychiatric illness, with conflicting results
(Silberberg et al., 2012; Zhu et al., 2012). However, given that the studies only addressed
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mRNA editing effects, there may be an alternative large scale regulatory impact of
ADARs on miRNA regulation of gene expression, which remains to be explored.

3.2.2 Schizophrenia and miRNAs
Schizophrenia is a severe mental illness that has an average lifetime development risk of
0.7%, with an average annual incidence rate of 15 per 100,000 (Blanchard et al., 2011;
Tandon et al., 2008). Heritability of the disease is estimated at 81% based on twin studies
(Sullivan PF, 2003). The term schizophrenia meaning, “split mind” was coined by
Bleuler in 1911 to describe the dissociation of thought, ideas, identity, and emotion that
characterize the illness (Moskowitz and Heim, 2011). The disease is described by
negative symptoms of social withdrawal, positive symptoms of psychosis including
hallucination and delusion, cognitive impairment, and in some cases mood dysregulation
(van Os and Kapur, 2009). These symptoms lead to secondary disparities in health and
premature mortality, stressing the need for better understanding of the underlying
mechanisms.
This mental illness is largely heterogenetic, with different patients having different
associated genetic alterations and varied symptomology (Green et al., 2012; Wahlsten,
2012). Evidence also suggests that it is a polygenic disorder, in which many common
genetic variants may each contribute a small increased risk (Purcell et al., 2009). Given
this evidence for such polygenicity and the fact that single miRNAs have the potential to
regulate hundreds to thousands of transcripts (Selbach et al., 2008), it seems plausible
that disruption of a miRNA could lead to abnormal expression levels of many genes,
which could in turn contribute to schizophrenia vulnerability. Many miRNAs were found
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to be differentially expressed in blood samples and postmortem tissue of patients with
schizophrenia, (Beveridge et al., 2009; Gardiner et al., 2011; Kim et al., 2010; Lai et al.,
2011; Miller et al., 2012; Moreau, et al., 2011; Perkins et al., 2007; Santarelli et al., 2011)
providing further evidence that miRNAs may impact the disorder.
One miRNA of particular interest is hsa-miR-137. The recent study from The
Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium (Ripke
et al., 2011), with an initial sample size of 21,856 and a replication sample of 29,839
found several new significant loci to be associated with schizophrenia, the strongest
association being the single-nucleotide polymorphism (SNP) rs1625579 within an intron
containing the primary transcript of miR-137. Several of the other associated loci
contained predicted targets of miR-137 (Ripke et al., 2011) supporting evidence that
miR-137 might play a role in the disorder. A subsequent smaller GWAS study examining
a smaller sample of patients with treatment-resistant schizophrenia from the United
Kingdom receiving clozapine treatment, also found significant association for
CACNA1C but did not replicate the finding for CSMD1 or miR-137, yet when the data
was grouped with the earlier GWAS study both were found to be significant (Hamshere
et al., 2012).
Besides GWAS studies, two additional experimental approaches are beginning to shed
light onto the possible link between miR-137 and schizophrenia. First, using luciferase
reporter assays, Kwon et al., 2011 confirmed that transcripts of other genes associated
with schizophrenia in the largest GWAS study (Ripke et al., 2011), namely CSMD1,
C10orf26, CACNA1C, and TCF4 can in fact be regulated by miR-137. Likewise, (Kim et
al., 2012) recently demonstrated that ZFN804A another gene highly associated with the
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illness (O’Donovan et al., 2008; Steinberg et al., 2011) can also be silenced by miR-137
in vitro. While further research is required to confirm the association of the SNP in miR137 with risk for schizophrenia, the findings that miR-137 can regulate the expression of
other schizophrenia associated genes provides new clues on how miR-137 may play a
role in the illness. Along these lines, a recent post-mortem tissue study suggests that the T
risk allele of rs1625579 may be associated with decreased miR-137 expression in the
dorsolateral prefrontal cortex of patients (Guella et al., 2013), further suggesting a
potential dysregulation of the miRNA’s targets.

3.2.3 Role of miRNA in brain development and function
miR-137 is expressed in embryonic and adult brains (Sun et al., 2011) and was found to
be highly enriched in synaptosomes from P15 rats (Siegel et al., 2009). Using in situ
hybridization high expression of this microRNA was observed in the dentate gyrus, an
area highly active in adult neurogenesis (Smrt et al., 2010).The involvement of this
miRNA in neuronal development was confirmed by several functional experiments.
Overexpression of miR-137 was shown to decrease proliferation of mouse embryonic
neural stem cells leading to their premature neuronal differentiation (Sun et al., 2011) and
similar effects were observed in adult mouse neural stem cells derived from the
subventricular zone or from brain tumors (Silber et al., 2008). However, overexpression
of miR-137 in the adult neural stem cells derived from the subgranular layer of the
dentate gyrus was found to disrupt the expression of stage specific differentiation markers
such as DCX and NeuN as well as dendritic arborization in these newly generated
neurons (Smrt et al., 2010). This apparent discrepancy is likely due to distinct roles of
miR-137 in different stages of neuronal differentiations as well as the intrinsic properties
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of cells in different neurogenic zones. In a recent study, overexpression of miR-137 was
shown to decrease maturation and increase proliferation while antagonism of miR-137 in
adult neural stem cells increased neuronal differentiation and reduced proliferation
(Szulwach et al., 2010). These experiments suggest that a balanced expression of miR137 is necessary to maintain appropriate neuronal differentiation and proliferation and
thus regulate neurogenesis. Given the important role that neurogenesis plays in learning,
memory, and mood regulation, disruption of these essential functions may have
significant effects that could lead to some of the symptomology seen in schizophrenia
(DeCarolis and Eisch, 2010).

3.2.4 Association of miR-137 and cognitive function
Recent genetics imaging studies have also found a correlation of miR-137 with
schizophrenia. Firstly, utilizing gene set enrichment analysis to assess the contribution of
gene regulatory networks to the illness, (Potkin et al., 2010) found that miR-137 was
implicated in two individual GWAS imaging genetics studies of patients performing the
Sternberg Item Recognition Paradigm (SIRP) working memory task (Potkin et al., 2009a;
Potkin et al., 2009b). Given the findings of the large 2011 GWAS study (Ripke et al,
2011), a subsequent study examining subjects at risk for schizophrenia and bipolar
disorder differentiated their cohorts based on this SNP (Whalley et al, 2012). Subjects
with two copies of the “T” risk allele were assigned as risk positive and those carrying
one or no copies of the allele were classified as risk negative subjects. A reduced
response in the right posterior medial frontal gyrus region to increasingly difficult
sentence completion tasks was noted only in the risk positive group across all the groups:
schizophrenia at risk, bipolar at risk, and controls. This suggests that miR-137 may have
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a general effect on executive function. Also, schizophrenia at risk subjects had
differential activation of the left amygdala and left pre/postcentral gyrus, suggesting a
more schizophrenia-specific effect of the allele as well (Whalley, et al., 2012).
Recent studies also examined the role of this miRNA on other functional
endophenotypes. The risk allele in miR-137 was potentially associated with the P300
endophenotype in schizophrenia patients (Decoster et al., 2012). In addition, when
combined with greater negative symptoms, the rs1625579 SNP genotype predicted
membership of patients in a subgroup with severe cognitive deficits, (Green et al., 2012).
In this study, cognitive functioning was evaluated by a battery of tests such as the LetterNumber Sequencing test to assess working memory, and the Controlled Oral Word
Association Test to assess executive function. First patients were categorized based on
their performance with this battery of tests into either a cognitive deficit group or a
cognitive spared group. Patients with more severe negative symptoms and the “G”
protective allele were surprisingly more likely to have been previously grouped in the
cognitive deficit group (Green et al, 2012). Another study examining carriers of the risk
allele among psychosis patients, including those with schizophrenia, schizoaffective
disorder and bipolar affective disorder I, found that carriers, particularly those
homozygous for the “T” risk allele, had lower scores for psychotic symptoms and a
subtle deficit in performance of episodic memory and attention control tasks (Cummings
et al., 2012).
While studying the clinical effects of chromosome 1p21.3 microdeletions, the region
containing the MIR137 gene,(Willemsen et al., 2011) found an association with
intellectual disability and autism disorder spectrum-like behavior. Furthermore,
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lymphoblastoid cell lines from these patients were found to have reduced levels of miR137 and enhanced levels KLF4 and the previously verified target genes MITF and EZH2.
The authors also confirmed that miR-137 is highly expressed in the hippocampus,
occipital cortex, and frontal cortex in human postmortem tissue, as well as in the
synaptosomal fractions in mouse brain preparations, providing further evidence that miR137 may play a role in synapse formation during brain development and function.

3.3 Targets of miR-137
To further understand the possible mechanism of miR-137 in schizophrenia, we used
available databases and the literature to identify putative and validated targets. Using the
list of potential and experimentally-verified targets, we then evaluated their chromosomal
location and temporal patterns of expression. Finally, we examined how these targets
cluster within biological pathways to identify which functions would be affected if miR137 levels were dysregulated as shown by initial post-mortem tissue studies (Guella et al,
2013).

3.3.1 Putative targets
Putative targets were identified by querying the publically available TargetScan Human
release 6.2 database updated June 2012 for hsa-miR-137 (Friedman et al., 2009a).
Selecting for target genes respective to site conservation resulted in 1144 putative target
genes. The Ensemble cytoband location for each gene was identified by querying for each
gene offered in the freely available GeneCards encyclopedia at www.genecards.org
(Stelzer et al., 2011). All subsequent analyses were performed using this list, as
TargetScan offers several advantages over other target prediction algorithms given its
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unique consideration for sequence context in addition to conservation and seed sequence
complementarity (Friedman et al., 2009; Grimson et al., 2007). This list was then
evaluated to identify targets studied for experimental validation in the following section.
Examining genes that may play a role in schizophrenia, we compared our putative target
lists against a schizophrenia-associated gene list of 278 protein-coding genes from the
publicly available schizophrenia gene resource (SZGR) ,a database of a variety of
schizophrenia related gene lists (Jia et al., 2010). We chose to use the association studies
gene list that is derived from the SchizophreniaGene (SZGene) database and further
evaluated for consistency across studies using a combined odds ratio (OR) method (Sun
et al., 2008). Of the 1144 TargetScan putative target list, 25 genes intersected with the
SZGR schizophrenia associated gene list. These genes are listed in Table 3.1, including
cytoband location information identified from GeneCards. Estimating that there are
20,000 genes in the genome, and that 278 are considered risk genes for schizophrenia, the
probability that a randomly chosen sample of 1144 genes contains 25 or more of these
risk genes is 0.017. Therefore, this result suggests that miR-137 targets are enriched in
schizophrenia risk genes.
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Gene
Symbol
ACSL6
ATXN1
BRD1
C18orf1
CHGA
ERBB4

Full Name

Cytoband

acyl-CoA synthetase long-chain family member 6
ataxin 1
bromodomain containing 1
chromosome 18 open reading frame 1
chromogranin A (parathyroid secretory protein 1)
v-erb-a erythroblastic leukemia viral oncogene
homolog 4 (avian)

5q31.1
6p22.3
22q13.33
18p11.21
14q32.12
2q34

FOXP2
FXYD6

forkhead box P2
FXYD domain containing ion transport regulator 6

7q31.1
11q23.3

FZD3
GABRA1

frizzled homolog 3 (Drosophila)
gamma-aminobutyric acid (GABA) A receptor,
alpha 1
glutamate receptor, ionotropic, AMPA 1
glutamate receptor, ionotropic, AMPA 4
glutamate receptor, ionotropic, N-methyl Daspartate 2A

8p21.1
5q34

GRM5
GSK3B
HTR2C
IMPA2

glutamate receptor, metabotropic 5
glycogen synthase kinase 3 beta
5-hydroxytryptamine (serotonin) receptor 2C
inositol(myo)-1(or 4)-monophosphatase 2

11q14.3
3q13.33
Xq23
18p11.21

MLC1

megalencephalic leukoencephalopathy with
subcortical cysts 1

22q13.33

NRG2
NRG3
PLXNA2
SYN2
SYN3
TNXB

neuregulin 2
neuregulin 3
plexin A2
synapsin II
synapsin III
tenascin XB; tenascin XA pseudogene

5q31.2
10q23.1
1q32.2
3p25.2
22q12.3
6p21.33

TSNAX

translin-associated factor X

1q42.2

GRIA1
GRIA4
GRIN2A

5q33.2
11q22.3
16p13.2

Table 3.1. SZGR associated miR-137 target genes*
*This list is derived from the intersection of the 1144 TargetScan putative target list with the SZGR
schizophrenia associated gene list. Cytoband location information was identified using GeneCards.
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3.3.2 Experimentally verified targets
Twenty-six experimentally verified targets were identified using the publicly available
database TarBase (Vergoulis et al., 2012) and manual literature searches (Table 3.2). The
functional targeting of these targets by miR-137 was confirmed by luciferase expression
reporter and Western blot assays in a variety of cell lines. A PubMed search of miR-137
resulted in 44 articles, 16 of which had abstracts mentioning target gene validation
experiments, which were further evaluated for their relevance. Only targets reported in
articles using functional validation assays were included except for KLF4, which was
confirmed by qPCR in an animal model over-expressing miR-137 (Willemsen et al,
2011). A subsequent search of hsa-miR-137 yielded no more unique articles from the
previous search. Of note, ZNF804A, a gene implicated in schizophrenia in several studies
(O’Donovan et al., 2008; Steinberg et al., 2011; Walton et al., 2013) (O’Donovan et al.,
2008 Steinberg et al., 2011, and Walton et al., 2012) was experimentally verified (Kim et
al., 2012) although it was not included in the TargetScan putative target list, presumably
because of the poor conservation of its binding site.
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Verified Target
CTBP1
CDC42

Assay
Ago2 binding assay,
luciferase assay
Western blot,
luciferase assay

Cell Lines
HEK293, A375

Reference
Deng et al., 2011

Source
TarBase

SW116, Lovo,
Hela, AGS,
MKN45
U251,OSCC,
HEK293

Liu et al., 2011;
Chen et al., 2011a

TarBase

Silber et al., 2008;
Kozaki et al., 2008;
Chen et al., 2011b
Balaguer et al.2010;
Sun et al., 2011

TarBase

Kozaki et al. 2008

TarBase

CDK6

luciferase assay,
Western blot

KDM1A (LSD1)

Luciferase assay,
Western blot

E2F6

Western blot

HCT116,
HEK293, neural
stem cells
OSCC

NCOA2

Western blot

OSCC

Kozaki et al. 2008

TarBase

MITF

luciferase assay,
GFP reporter

HEK293, A375,
WM852

Literature Search

KDM5B (Jarid1b)
SPTLC1

Western blot,
luciferase assay
luciferase assay

PTBP1

luciferase assay

mouse ESC,
HEK293
rat primary
astrocytes
Neuro2a cells

Haflidadóttir et al.,
2010;
Chen et al., 2011b;
Bemis et al., 2008
Tarantino et al.,
2010
Geekiyanage and
Chan, 2011
Smith et al., 2011

CSMD1#

luciferase assay

HEK-293T

Kwon et al., 2011

Literature Search

C10orf26#

luciferase assay

HEK-293T

Kwon et al., 2011

Literature Search

CACNA1C#

luciferase assay

HEK-293T

Kwon et al., 2011

Literature Search

TCF4#

luciferase assay

HEK293T

Kwon et al., 2011

Literature Search

CDK2

Western blot

M23 and SP6.5

Chen et al., 2011b

Literature Search

RB1 (p-Rb)

Western blot

M23 and SP6.5

Chen et al., 2011b

Literature Search

MAPK1 (p-ERK1/2)

Western blot

M23 and SP6.5

Chen et al., 2011b

Literature Search

MAPK3 (p-ERK1/2)

Western blot

M23 and SP6.5

Chen et al., 2011b

Literature Search

MET (c-Met)

Western blot

M23 and SP6.5

Chen et al., 2011b

Literature Search

ESRRA

luciferase assay

HepG2

Zhao et al., 2012

Literature Search

PTGS2 (Cox-2)*

Western blot,
luciferase assay
luciferase assay

U87 and LN229

Chen et al., 2012

Literature Search

Smrt et al., 2010

Literature Search

Vo et al., 2011

Literature Search

Szulwach et al.,
2010
Willemsen et al.,
2011

Literature Search

Kim et al., 2012

Literature Search

MSI1

Western blot,
luciferase assay

DIV6 primary
neurons
U251,Daoy,
HeLa

EZH2

luciferase assay

HEK293T

KLF4

quantitative reverse
transcription PCR in
overexpressing
miR-137 animal
model
luciferase assay

LCL

MIB1

ZNF804A

HEK293T, Be2C

Table 3.2. Experimentally verified targets of hsa-miR-137
*indicates genes in SZGR associated list
# indicates genes associated with schizophrenia but not in SZGR list

39

TarBase,
Literature Search

Literature Search
Literature Search
Literature Search

Literature Search

3.3.3 Chromosomal location of target genes
Cytoband data was gathered from the UCSC database table browser, assembly dated
February 2009 http://genome.ucsc.edu/ (Karolchik, 2004). miR-137 target gene location
data was identified using the GeneCards database. This data was graphed using the
Matlab Bioinformatics Toolbox (Figure 3.2). Target genes are located throughout the
genome with a few localized “hot spots” (shown by red vertical lines in the figure). There
are several “hotspots” located in Chromosomes 1, 11, 12, 16, and one each in
chromosome 3,14,17,19, and X. Comparison of the cytoband locations with miR-137
targets and those known to be affected by copy number variations (CNVs) in
schizophrenia and autism spectrum disorders (ASD) (Liu et al., 2012; Sullivan et al.,
2012) revealed several regions of overlap. While the proportion of overlapping cytobands
did not reach global statistical significance with a hypergeometric probability test, it is
important to note that one of these regions mapped to NRXN1, a 2p16.3 gene with
associated deletions in both schizophrenia and ASD and whose transcript is a putative
miR-137 target.
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Figure 3.2 miR-137 Target Gene Locations. Karyotype representing cytoband locations of the miR-137
TargetScan putative target genes. Blue depicts cytobands with 2-5 target genes. Red indicates regions
containing 6 or more target genes.

3.4 Functional relevance of target genes
3.4.1 Expression of target genes
Given that the onset of schizophrenia generally occurs in adolescence and early
adulthood, we reviewed the temporal expression patterns of miR-137 target genes. Using
the freely available BrainCloud expression database developed by the Lieber Institute for
Brain Development (LIBD) and the National Institute of Mental Health (NIMH)
(Colantuoni, et al., 2011) that uses the expression profiles in the dorsolateral prefrontal
cortex of human postmortem tissue across the lifespan, we examined the expression
patterns of all available experimentally verified target genes (Table 3.2) and putative
targets common to the SZGR association list (Table 3.1). Except for ATXN1, CDC42,
GRIN2A, KDM1A (LSD1), and SYN3 we found expression patterns for all these genes.

41

Of the 46 examined genes, about 41 percent have peak expressions during prenatal life,
13 percent during prenatal and postnatal combined, 20 percent postnatal, 4 percent both
post-natal and adult and 22 percent during adulthood (Figure 3.3). Comparison of the
patterns of expression of miR-137 targets vs. whole brain transcriptome (Kang et al,
2011) revealed that the targets have an atypical temporal distribution with peak
expressions occurring more often during the prenatal period, or during adult life. The
findings that 74 percent of target genes have peak expressions prior to adulthood,
particularly prenatally, suggest that these target genes may be particularly relevant to the
development of the schizophrenia. The unexpectedly large proportion of genes with peak
expression in adulthood raises the possibility that miR-137 targets are involved in the
ongoing decline in cognitive function and gray matter density observed in schizophrenia
over the lifespan.
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Figure 3.3 Peak Expression Life Stage for Genes of Interest. Temporal expression data for all available
miR-137 putative targets and verified targets is based on the BrainCloud Database (Kang et al., 2011).
Comparison of the temporal expression profiles of miR-137 targets and whole brain transcriptome
(BrainCloud) using Chi square analysis revealed that the temporal expression profile frequency
distributions were significantly different (p < 0.01). The prenatal stage is defined as week 14 through birth,
postnatal stage is defined as birth through age 20 years, and adult stage is defined as age 20 years and older.

3.4.2 Pathway analysis
Pathway analysis was performed using the putative target gene list derived from
TargetScan, containing 1144 target genes and the 8 experimentally verified target genes
(Table 3.2) not contained within the putative list. This analysis was performed in three
levels using the Ingenuity Pathway Analysis (IPA) software (Ingenuity® Systems, CA,
USA, www.ingenuity.com) generating a canonical pathway analysis and related network
analyses for each level. The networks are given a score based on the probability of
inclusion of the number of molecules in the generated networks over the probability of a
network being generated by chance with random molecules. This score is generated as a
negative log p value based on a right tailed Fisher’s exact test (Calvano et al., 2005).
Canonical pathway analysis is performed by comparing the dataset of interest against

43

known canonical (signaling and metabolic) pathways within the database. A negative log
p value is also assigned to the pathways based on a Fisher’s exact test of the probability
of the number of molecules from the user-created dataset included in the given pathways,
versus being included based on chance alone.
A core analysis was first performed with this data set analyzing molecules in all tissue
types in mammals. Of the 1144 putative target genes, 1142 were mapped in the IPA
software and usable for the analysis. In addition the 8 experimentally-verified transcripts
not included in this putative target list were all mapped in IPA and included in the
analysis, so that a total of 1150 target genes were used in the analysis. The top scoring
canonical pathways corresponding to targets expressed a) in all tissues, b) only in the
nervous system (NS) or c) those associated with NS development and function are shown
in Figure 3.4.
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Figure 3.4 IPA canonical pathway analyses from each tier of core analysis. The X axis represents
negative log p values based on the probability that molecules in the uploaded dataset were included the
predefined IPA canonical pathways by true association as opposed to inclusion of molecules based on
chance alone. Pathways not involved in nervous system were removed from the nervous system tissue
analysis and nervous system development and function graphical displays. Only the top ten pathways with
the largest negative log p values are shown. The dashed line indicates the threshold of significance for a p
value of 0.01. GNRH, Gonadotropin-releasing hormone, HGF, hepatocyte growth-factor, NMJ,
neuromuscular junction.
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Interestingly, while Sertoli cell-signaling was the top scoring pathway for targets
expressed in all tissues, this set also included several nervous system-specific pathways.
Among these, the top scoring pathways were agrin interaction at the neuromuscular
junction, and synaptic long-term potentiation. The top physiological system associated
with miR-37 targets, containing 202 genes, was nervous system development and
function. Using this set, we found that the top pathways were Ephrin receptor signaling,
and axonal guidance, processes known to be involved in neuronal development and
cognition.
The biological significance of the molecules included in these canonical pathways is best
illustrated by their associated interactive networks (Figures 3.5-3.7). As shown in Figure
3.5, the top networks of targets expressed in all tissues contained a large number of
nervous system associated molecules, depicted in yellow, confirming past studies that
miR-137 is involved in nervous system development (Siegel et al., 2009; Silber et al.,
2008; Smrt et al., 2010; Sun et al., 2011; Szulwach et al., 2010).
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Figure 3.5. Top 3 scoring IPA network analysis generated networks for all mapped 1150 TargetScan
putative targets and verified targets. The top 3 scoring networks identified were: (A)“Hereditary
Disorder, Neurological Disease, Skeletal and Muscular Disorders,” with a score of 39, (B)“Cellular
Development, Connective Tissue Development and Function, Cancer,” with a score of 39, and (C) “Protein
Synthesis, Endocrine System Development and Function, and Lipid Metabolism,” with a score of 36.
Yellow indicate molecules expressed in the nervous system. White molecules are those not included in the
uploaded dataset but added by IPA. Gray molecules indicate those that were included in the uploaded
dataset. Relationships depicted by lines with arrows represent “act on,” while lines without arrows
represent binding. See figure keys for identification of the types of molecules included.

A subsequent core analysis was then performed with the 929 nervous system tissue
associated subset of molecules of the original 1150 putative and verified target genes
used in the previous analysis. This resulted in networks (Figure 3.6) including a
substantial number of target genes found in the SZGR database and the experimentally
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verified list, as well as many other schizophrenia-associated genes. Finally, the top
association networks of targets involved in nervous system development and function
also contained many of the schizophrenia associated and verified target genes (Figure
3.7).

Figure 3.6 Top 3 scoring IPA network analysis generated networks for the 929 nervous tissue specific
putative and verified targets. The top 3 scoring networks identified by this analysis were: (A) “Hereditary
Disorder, Neurological Disease, Skeletal and Muscular Disorders,” with a score of 35, (B) “Neurological
Disease, Cell-To-Cell Signaling and Interaction, Nervous System Development and Function,” with a score
of 10, and (C) “Behavior, Cell-To-Cell Signaling and Interaction, Nervous System Development and
Function,” with a score of 8. White molecules are those not included in the uploaded dataset but added by
IPA. Gray molecules indicate those that were included in the uploaded dataset. Relationships depicted by
lines with arrows represent “act on,” while lines without arrows represent binding. See figure legend keys
for identification of the types of molecules included. Blue outlines depict experimentally validated targets
and those in red indicate SZGR associated targets.
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Figure 3.7.Top 3 scoring IPA network analysis generated networks for 202 nervous system
development and function subset of putative and verified targets. The three top scoring networks
identified were: (A) “Behavior, Hereditary Disorder, Neurological Disease,” with a score of 29, (B) “Cell
Morphology, Cellular Assembly and Organization, Cellular Development,” with a score of 12, and (C)
“Cell-To-Cell Signaling and Interaction, Nervous System Development and Function, Neurological
Disease,” with a score of 10. White molecules are those not included in the uploaded dataset but added by
IPA. Gray molecules indicate those that were included in the uploaded dataset. Relationships depicted by
lines with arrows represent “act on,” while lines without arrows represent binding. See figure keys for
identification of the types of molecules included. Blue outlines depict experimentally validated targets and
those in red indicate SZGR associated targets
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3.5 Conclusions and perspectives
There is evidence that schizophrenia is a highly complex polygenic disorder with
multiple genes contributing only a small risk. Given that individual miRNAs can affect
the expression of up to thousands of genes post-transcriptionally, and that differential
expression of miRNAs between patients with schizophrenia and controls has been shown
in many different studies; it seems likely that miRNAs may play a role in the etiology of
the disease. miR-137 in particular was shown to have a SNP (rs1625579) with the highest
association with schizophrenia in the largest schizophrenia GWAS study performed to
date (Ripke et al, 2011). Although the mechanisms by which this SNP may cause a
dysregulation in miR-137 processing is not completely understood, recent studies suggest
that carriers of the risk allele have abnormal levels of mature miR-137 in the cerebral
cortex (Guella et al, 2013). Considering the biological pathways associated with miR-137
targets, there are several possible mechanisms, discussed below, by which alterations in
miR-137 expression may contribute to the development and pathophysiology of
schizophrenia.
Imaging genetics studies have shown an association of the miR-137 risk allele with
reduced fMRI responses in both patients and at risk subjects while performing cognitive
tasks (Potkin et al., 2010, Potkin et al., 2009a; Potkin et al., 2009b; Whalley, et al., 2012).
In addition, this SNP was also shown to have a potential association with the P300
endophenotype (Decoster et al., 2012) and a significant association with cognitive
deficits in patients with schizophrenia using a variety of tasks (Green et al., 2012,
Cummings et al., 2012). Furthermore, a recent study (Lett et al, 2013) found that the risk
allele was associated with earlier age-at-onset of psychosis, decreased hippocampal
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volume, and reduced white matter integrity throughout the entire brain. Given that miR137 plays a role in neurogenesis, neurodevelopment, dendritic arborization and is located
in the synapse (Siegel et al., 2009; Silber et al., 2008; Smrt et al., 2010; Sun et al., 2011;
Szulwach et al., 2010) it is enticing to propose that abnormal expression of this miRNA
may lead to abnormal synapse formation which could in turn play a role in the cognitive
deficits, psychotic symptoms and brain structural abnormalities found in these patients.
By utilizing the freely accessible TargetScan, GeneCards, and UCSC databases, we found
that the miR-137 potentially targets over a thousand genes, with a variety of functions
and potential impact. As depicted in Figure 3.2, these putative target genes can be found
throughout nearly every chromosome, with some particular regions of high concentration.
This list of putative target genes also includes some known to be associated with
schizophrenia (e.g., ERBB4, GABRA1, GRIN2A, GRM5, GSK3B, NRG2 and HTR2C)
as well as many experimentally verified as true targets. Subsequent analysis of these
putative and verified genes using IPA demonstrates that this list of genes includes many
nervous system specific genes. Expression Data from BrainCloud also confirms that
many of the genes such as FXYD6, BRD1, GSK3B, CDK6, CDC42, and CACNA1C
have higher expression levels in onset risk time periods, suggesting their relevance in
contributing risk for development of schizophrenia. These target genes also form
networks involved in neuronal function and development; with the top canonical
pathways associated being agrin interaction at the neuromuscular junction, synaptic
long term potentiation (LTP), Ephrin receptor signaling, and axonal guidance signaling.
Sertoli cell signaling was the top scoring pathway identified by the first tier of analysis of
all 1150 putative and verified targets of miR-137, which may be related to the increased
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risk of schizophrenia with increasing paternal age (Frans et al., 2011). The identification
of agrin interaction at neuromuscular junctions as a top canonical pathway may also be of
interest given the association with neurological soft signs and schizophrenia (Sewell et
al., 2010). Also, given that several of the same target transcripts play a role in cell-cell
interactions in the periphery and the CNS, it is likely that this miRNA has similar roles in
other tissues. However, given the enrichment of this mRNA in developing neurons, we
focus our discussion in this cell type.
Many of the top scoring pathways identified: LTP signaling, Ephrin receptor signaling,
and axonal guidance signaling, are closely linked to learning and memory and have
shown to be associated with schizophrenia. A recent study suggests evidence of impaired
LTP in schizophrenia patients with a simultaneous deficit in motor learning(Frantseva et
al., 2008). In addition, many schizophrenia animal model studies have also demonstrated
an impairment of LTP (Pollard et al., 2011). Of particular interest, a study examining
ERBB4 (one of the miR-137 putative target genes), and synaptic potentiation,
demonstrated that mice with a full ErbB4 knock-out and mice with a conditional ErbB4
knock-out in only parvalbumin expressing cells exhibit increased hippocampal LTP and
lack theta-pulse evoked LTP reversal (Shamir et al., 2012). These mice have increased
locomotor activity in the open field test; such hyperactivity in response to novelty is used
often as a model of positive symptomatology in schizophrenia. The mice also exhibit
deficits in prepulse inhibition of the acoustic startle response, a test believed to model
sensorimotor gating, which has been shown to be reduced in patients with schizophrenia.
These findings provide further evidence that miR-137 may indeed impact LTP in
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schizophrenia leading to the cognitive dysfunction, a clinical feature still poorly
understood and inadequately treated (Blanchard et al., 2011).
Axonal guidance has also been implicated in schizophrenia. Ephrin signaling plays a role
in axonal guidance by controlling axon motility (Xu and Henkemeyer, 2012). A recent
imaging study found an association between polymorphisms in RELN and PCDH12,
genes involved in neuronal guidance and synaptic formation, and alterations in the
patients’ brain structure as seen by MRI (Gregorio et al., 2009). Another imaging study
found an association with SNPs in RELN, PLXNA2 and other genes involved in axonal
guidance and neuronal development and prediction of DLPFC inefficiency during a
working memory task (Walton et al., 2013). There is also evidence linking Ephrin
receptor signaling and LTP. Particularly two studies found that postsynaptic EphB
receptors and presynaptic B-ephrins are necessary for the induction of LTP of the mossy
fibers in the hippocampus, a N-methyl-D-aspartate (NMDA) receptor independent form
of LTP (Armstrong et al., 2006). Of note, many genes involved in glutamate signaling
such as GRIA1, GRIA4, GRIN2A, GRM2, and GRM5 were identified in the generated
networks and were included in the LTP signaling cascade of the IPA canonical pathway.
The potential role of miR-137 in the expression of these glutamate receptors could
explain not only the altered glutamate signaling observed in schizophrenia (Coyle, 2006;
Sendt et al., 2012), but also the LTP disruption in the illness, which may in turn
contribute to the associated cognitive deficits.
Interestingly, we also found that the Huntington’s associated protein huntingtin (HTT)
was identified as a hub in all three tiers of IPA network analyses. While the normal
function of this protein is still largely unknown, it is possible that HTT has been included
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in the IPA database as having many biological relationships largely because it is well
studied. However, recent evidence suggests that HTT is involved highly in neuronal
development, playing a role in early neuronal survival, regulation of axonal transport,
regulation of BDNF production particularly in the cortex, and controlling synaptic
activity (Zuccato et al., 2010). Given the role of miR-137 in neuronal development, these
two molecules may work in concert to regulate this process. Further research will be
necessary to determine if HTT plays a role in schizophrenia.
By IPA analysis of the putative and experimentally validated targets of miR-137, we
identified that a large majority are expressed in the nervous system, forming networks
involving genes associated with schizophrenia. The top canonical pathways identified by
these analyses are widely known to be associated with learning and memory and synaptic
formation, suggesting that the genetic impact of this miRNA may play a role in the
processes of cognition and neuronal development. While our own analyses and the results
of the literature support a role of miR-137 in the etiology of schizophrenia, further
analysis is necessary to understand the full impact of this miRNA. In particular, it will be
important to evaluate the involvement of LTP, Ephrin receptor signaling, axonal
guidance, and glutamate signaling. Further elucidation of the role of miR-137 in
schizophrenia is merited as the negative symptoms and cognitive deficits associated are
still inadequately treated and can have such a grave impact on patients. This miRNA may
provide a new avenue for exploring the underlying mechanisms involved in the etiology
of the disease as well as discovering new biomarkers and therapeutic targets.
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4.1 Abstract
Background: A single nucleotide polymorphism (SNP) within MIR137, the host gene for
miR-137, has been identified repeatedly as a risk factor for schizophrenia. Previous
pathway analyses suggest that potential targets of this microRNA (miRNA) are also
highly enriched in schizophrenia-relevant biological pathways, including those involved
in nervous system development and function.
Methods: In this study, we evaluated the schizophrenia risk of miR-137 target genes
within these pathways. Gene set enrichment analysis of pathway-specific miR-137 targets
was performed using the stage 1 (21,856 subjects) schizophrenia genome wide
association study data from the Psychiatric Genomics Consortium and a small
independent replication cohort (244 subjects) from the Mind Clinical Imaging
Consortium and Northwestern University .
Results: Gene sets of potential miR-137 targets were enriched with variants associated
with schizophrenia risk, including target sets involved in axonal guidance signaling,
Ephrin receptor signaling, long-term potentiation, PKA signaling, and Sertoli cell
junction signaling. The schizophrenia-risk association of SNPs in PKA signaling targets
was replicated in the second independent cohort.
Conclusions: These results suggest that these biological pathways may be involved in the
mechanisms by which this MIR137 variant enhances schizophrenia risk. SNPs in targets
and the miRNA host gene may collectively lead to dysregulation of target expression and
aberrant functioning of such implicated pathways. Pathway-guided gene set enrichment
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analyses should be useful in evaluating the impact of other miRNAs and target genes in
different diseases.

4.2 Background
MicroRNAs (miRNAs) are a class of noncoding RNAs involved in post-transcriptional
gene expression regulation by binding to complementary sequences within target mRNAs
(Bartel, 2009). miRNAs play a role in a variety of cellular processes and diseases
(Henrion-Caude et al., 2012), including psychiatric disorders (Mellios and Sur, 2012).
Several lines of evidence support a role of miR-137 in schizophrenia, a severe mental
illness characterized by symptoms of delusions, hallucinations, and diminished
sociability Not only was the strongest associated SNP identified in the first large
schizophrenia genome wide association study (GWAS) located in the host gene of miR137 (Ripke et al., 2011) but also the other top four polymorphisms mapped to validated
target genes of this miRNA (Kwon et al., 2011). This miRNA is involved in several steps
in neuronal development, from regulation of neuronal proliferation and differentiation
(Silber et al., 2008; Smrt et al., 2010; Sun et al., 2011; Szulwach et al., 2010a), to
dendritic arborization (Smrt et al., 2010) suggesting that the risk allele may impact these
processes. Additionally, imaging genetics studies have found distinct alterations
associated with the MIR137 risk variant in subjects with schizophrenia. One recent
functional magnetic resonance imaging (fMRI) study identified alterations in brain
activity patterns during a sentence completion task within the amygdala and pre and
postcentral gyrus only in risk allele carrier subjects that were also at risk for
schizophrenia development (Whalley et al., 2012). Structural imaging analyses also
identified patient-specific alterations in risk allele carriers such as reduced whole brain
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functional anisotropy, reduced left hippocampal volume and enlarged right and left lateral
ventricle volume (Lett et al., 2013). In contrast, no volumetric alterations were found in
protective-allele carrying patients or healthy risk allele carriers (Li and Su, 2013). The
disease-specific risk allele associations found in these studies suggest that, in agreement
with the evidence of polygenic risk in schizophrenia (Purcell et al., 2009), other genetic
factors besides the MIR137 SNP may underlie disease-specific abnormalities in brain
structure and function. Polymorphisms within multiple miR-137 targets may in part
increase genetic risk by potentially enhancing dysregulation by this miRNA. Variants
within or adjacent to miRNA recognition sites in 3’ UTRs can alter binding and binding
availability of miRNAs to target mRNAs, leading to altered gene expression and
phenotypic or disease states (Abelson, 2005; Wang et al., 2008) Therefore, collective
polymorphisms within miR-137 target genes in schizophrenia-relevant pathways may
disrupt regulation by this miRNA, and/or lead to a general disruption of the pathways in
the patients.
Initial bioinformatics analyses of the function of putative and validated targets suggest
that miR-137 target genes are involved in many schizophrenia relevant pathways,
including axonal guidance signaling, Ephrin receptor signaling, synaptic long term
potentiation (LTP), and protein kinase A (PKA) signaling, among others (Wright et al.,
2013). Besides LTP, little is known about the role of these miR-137 regulated pathways
in schizophrenia. Preliminary SNP by SNP association analyses performed by the PGC
found significant enrichment of risk associated SNPs within a subset of predicted miR137 target genes (Ripke et al., 2011) and this was replicated with a larger set of predicted
targets, using a joint gene set enrichment analysis (Ripke et al., 2013). However, no
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studies to date have examined the collective risk of miR-137 target SNPs across
biological pathways.

4.2.1 Overall Goals and Contribution
The goals of this study were to assess the schizophrenia-risk of both experimentally
validated and high confidence predicted miR-137 targets, and to evaluate for the first
time the risk association of these targets in a pathway-specific manner. These analyses
were performed using meta gene set enrichment analyses of specific target gene sets
(Segrè et al., 2010). Gene set enrichment analysis (GSEA) is particularly useful in the
case of polygenic diseases such as schizophrenia (Purcell et al., 2009) as it allows for
examination of the collective effect of multiple polymorphisms. Furthermore, analysis of
gene sets in a pathway specific framework can also increase the power to detect
collective moderate risk associations and can allows for evaluation of more biologically
relevant and interpretable genetic effects particularly with genetically complex disorders
(Juraeva et al., 2014). In this study we identified pathway-specific miR-137 target gene
sets, and evaluated their risk association both within the PGC Stage 1 GWAS data (Ripke
et al., 2011) and within a smaller independent dataset including subjects from the Mind
Clinical Imaging Consortium (MCIC) (Gollub et al., 2013) and Northwestern University
(NU) (Wang et al., 2013). The evaluation of pathway-specific gene sets in this manner
allows for an estimation of schizophrenia-risk due to miR-137 dysregulation.
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4.3 Methods
4.3.1 miR-137 Target Curation and Prediction
Experimentally validated targets and 2 indirectly regulated genes (MAPK1 and MAPK3)
were curated (36 in total) from the literature as described previously for the identification
of 26 regulated genes in Wright et al., 2013. Additionally HTT (Kozlowska et al., 2013),
TBX3 (Jiang et al., 2013), GLIPR1 (RTVP-1) (Ariel Bier et al., 2013), CLDN11,
GABRA1, NRXN1, NEFL, ZNF365, NECAP1, and RAPGEF5 (Boudreau et al., 2014)
were included as validation experiments were published since Wright et al., 2013..
Targets were predicted using TargetScan version 6.2, released June 2012 (Lewis et al.,
2005). Target prediction databases are known to include false positive miRNA-mRNA
interactions and to exclude true interactions (Zheng et al., 2013). TargetScan offers two
scoring systems to improve confidence in target-miRNA prediction: the probability of
conserved targeting (Pct) score and the context score. The Pct score (with a range from 0
to 1, with 1 indicating highest) is derived by evaluating the conservation of the
interaction site sequence across species (Friedman et al., 2009). Highly conserved
binding sites are more likely to be functionally relevant and effective in inducing
subsequent mRNA repression (Friedman et al., 2009; Nielsen et al., 2007) However,
target interactions that may have evolved later in primates and humans are less likely to
be conserved (Friedman et al., 2009; Glazov et al., 2008) and may be more relevant to
higher order cognition and complex behavior phenotypes, such as those affected in
schizophrenia. Thus some human-specific or primate-specific targets may be lost based
on conservation score (Farh et al., 2005; Grimson et al., 2007). The context score
provides confidence for the less conserved targets and improved confidence for
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conserved targets. This score (with a range from 0 to -1, with -1 indicating more probable
binding) is based on evaluation of site efficacy including seed site interaction type,
nearby nucleotides , site location, and seed site interaction stability among other criteria
(Garcia et al., 2011; Grimson et al., 2007). Therefore, site conservation and site efficacy
were both used, either separately or combined, to better capture the potential impact of
miR-137 on biological pathways.
The four predicted miR-137 target gene lists, each including validated targets, that were
curated for further analysis (Appendix A, Table A.1) included: a) the full target list as
predicted by TargetScan (full target list), b) targets with Pct scores greater than or equal
to 0.9 (conserved target list), c) targets with the best 50% of context scores (context target
list), and d)the high Pct and low context scoring targets (intersection target list). The Pct
score cutoff of 0.9 was based on previous work of Ripke et al., 2011. The context score,
with an equal percentage of predicted targets as that chosen for the Pct score, was -0.12.
Finally, the intersection of targets with Pct scores greater than or equal to 0.9 and with
context scores below -0.12 was used as a higher confidence predicted list that represents
more plausible conserved targets.

4.3.2 Pathway Selection Criterion
Selection of gene sets was based on prior pathway analysis of the full list of TargetScan
predicted targets and validated targets using Ingenuity Pathway Analysis (IPA) as
described previously in Wright et al., 2013. From this analysis, it was determined that
several possibly schizophrenia-relevant pathways were significantly enriched with
potential miR-137 target genes. The top ten enriched pathways for potential targets, listed
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in Table 4.1 were selected for pathway-specific gene set enrichment analyses. Gene sets
of miR-137 target genes of varied prediction confidence were created for each pathway
using the target gene lists described above (Appendix A, Table A.1).
Evaluated Gene Set in Full
MAGENTA
List
Gene Set size
1154
Pathway Specific Gene Sets:
Sertoli cell junction
27
signaling
Mechanisms of cancer
40
Hepatocyte growth
18
factor (HGF) signaling
Ephrin receptor
25
signaling
Agrin interactions at
neuromuscular
14
junctions
Gonadotropin
Releasing Hormone
20
(GNRH) signaling
Cardiac –B adrenergic
20
signaling
Synaptic long term
19
potentiation (LTP)
Protein kinase A (PKA)
42
signaling
Axonal guidance
42
signaling

Conserved Context
List
List
560
597

Intersection Validated
List
List
311
36

16

15

11

4

25

22

17

8

13

12

9

6

16

12

10

3a

9

8

6

3a

12

6

6

3a

10

4

2

1

11

7

4

3

26

18

10

4

20

18

13

3a

Table 4.1. Gene Sets of Potential hsa-miR-137 Targets Evaluated in MAGENTA
This table shows the number of potential miR-137 target genes evaluated in each gene list and the number
of genes in each pathway-specific gene set derived from each target gene list. MAGENTA= Meta Gene Set
Enrichment of Variant Analysis
a

identical gene sets
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4.3.3 Meta Gene Set Enrichment of Variant Analysis (MAGENTA)
The MAGENTA software program (Segrè et al., 2010) evaluates enrichment of modest
associations with a disease or trait within gene sets using GWAS disease association p
values and odds ratios. MAGENTA includes SNPs within a region from 110 kb upstream
to 40 kb downstream of each gene’s transcript boundaries. The SNP with the smallest
disease association p-value within this region is determined for later analysis as the
“gene’s best” association p-value. Such a procedure helps overcome the “watering-down”
effects that occur when analyzing the average SNP p-value across a gene, where
unassociated SNPs can depreciate gene association. The following confounds are
addressed by correcting the smallest gene SNP p-values with step-wise linear regression:
gene size, number of SNPs per gene kb, number of independent SNPs per gene kb,
number of recombination spots per gene kb, linkage disequilibrium units per gene kb, and
genetic distance per gene kb (Segrè et al., 2010).
MAGENTA uses corrected best gene disease association p-values to evaluate the
enrichment of each gene set with, in this case, genes containing a schizophreniaassociated variant. Gene sets are compared to 10,000 random gene sets of identical size.
The gene set p-value is calculated as the fraction of random gene sets with a sum rank pvalue equal or smaller than that of the tested gene set. Gene sets with a one-tailed MannWhitney like rank-sum based false discovery rate (FDR) (Sabatti et al., 2003) q-value of
<0.05 were considered significantly enriched with associated SNPs based on the FDR
gene score enrichment cutoff of 75%. This cutoff is based on the fraction of p-values
lower than 75% of all gene p-values and is suggested for polygenic diseases such as is
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proposed for schizophrenia (Purcell et al., 2009) where association values may be more
modest (Segrè et al., 2010)

4.3.4 Database and GWAS Information
To determine whether the gene sets in Table 4.1 are enriched in schizophrenia risk
variants, p-values from two independent GWAS were evaluated. The first p-values were
derived from the stage 1 GWAS study reported in Ripke et al., 2011, the GWAS in which
the schizophrenia risk association was discovered for the miR-137 host gene SNP,
rs1625579. This analysis included 21, 856 subjects (9,394 cases and 12,462 controls) of
European ancestry from the Psychiatric GWAS Consortium (PGC) (TableS3).
Genotyping was performed using Affymetrix and Illumina Chips across samples. Quality
control was conducted as described in Ripke et al., 2011. The unadjusted p-values and
odds ratios for the 1.2 million SNPs evaluated in this GWAS are available on the PGC
website, https://pgc.unc.edu/Sharing.php. GWAS p-values and odds ratios were loaded
into MAGENTA (Segrè et al., 2010) with one gene set file including all gene sets in
Table 4.1 to allow cross-comparison of gene sets, as permutation differences can cause
slightly different results.
To evaluate if the PGC MAGENTA results were replicable, subjects were analyzed from
the Mind Clinical Imaging Consortium (MCIC) (Gollub et al., 2013) and Northwestern
University (NU) (Wang et al., 2013) (Appendix A, Table A.2). All participants provided
written informed consent, and the Institutional Review Board at each site approved this
project. Genotyping was conducted at the Mind Research Network Neurogenetics Core
lab using Illumina HumanOmni-Quad 1M and 5M BeadChips respectively. Only

65

Caucasian subjects were used to avoid population-specific effects. Caucasians were
identified using the Enhancing Neuroimaging Genetics through Meta-Analysis
(ENIGMA) multi-dimensional scaling (MDS) protocol within the imputation protocol
(http://enigma.ini.usc.edu/protocols/genetics-protocols/). Genotype data from each
dataset was merged using PLINK after updating the MCIC SNP locations to match that
of the more recent NU data. Quality control was performed before and after merging
similarly to that of Ripke et al. 2011, using PLINK with the following thresholds: Hardy
Weinberg equilibrium P <10 -6, minor allele frequency < 0.05, missing rate per SNP <
0.02, missing rate per individual < 0.02. Relatedness and population stratification testing
was performed using PLINK. Outliers were identified and removed as well as one
individual per pair that appeared to be related, according to pi-hat values of 0.05 or
greater per pair of individuals. After all quality control and pruning, a total of 244
individuals remained (103 cases and 141 controls) and 539,288 SNPs.
A GWAS study using logistic regression covarying for chip type was performed on the
merged MCIC and NU genotypic data with a genomic inflation factor of 1.00737. The pvalues obtained were evaluated using MAGENTA for the previously significantly
enriched gene sets found in the PGC data.

4.4 Results
4.4.1 MAGENTA Analyses of miR-137 Predicted and Validated Target Lists
Gene sets for each of the target lists of different prediction confidences were first
evaluated for enrichment of schizophrenia risk SNPs (Table 4.2). The higher confidence
predicted lists, i.e., the conserved, context, and intersection, were all significantly
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enriched with schizophrenia-associated variants. As shown in Figure 4.1, the IPA
network derived from the 77 intersection targets that were associated with neurological
disease contains many nervous system expressed genes including some schizophreniaassociated genes that interact with one another. The validated target list was not
significantly enriched with variants, likely due to the small size of this set. The full list of
putative targets, although trending, was not enriched either, possibly due to a higher
inclusion of false positive miRNA-target interactions. This suggests that the high
confidence predicted miR-137 target genes overall contain SNPs that are associated with
schizophrenia.
Gene Set

Full List
Conserved
List
Context List
Intersection
List
Validated List

MAGENTA
Gene Set Size
1061

Nominal GSEA
p-value with
75% cutoff
1.32E-02

FDR q-value
with 75%
cutoff
5.11E-02

548

1.50E-03

1.96E-02

585

3.90E-03

1.89E-02

329

2.50E-03

1.90E-02

36

9.08E-02

9.75-02

Table 4.2. Curated hsa-miR-137 Target Gene Lists Show Enrichment for Association with
Schizophrenia
This table shows the results of the target gene lists including the number of genes after conversion to
ENTREZ IDs , the gene set enrichment analysis (GSEA) p-value before false discovery rate (FDR)
correction, and the FDR q-value used to determine significance at a threshold of q <0.05. Significant gene
lists are shown in bold. MAGENTA= Meta Gene Set Enrichment of Variant Analysis
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Figure 4.1. miR-137 Intersection Target Network of Neurological Disease
Top network derived from a core analysis using Ingenuity Pathway Analysis with the 77 genes of the
intersection target list that are associated with Neurological Disease. Predicted targets are indicated in
yellow, targets associated with schizophrenia are outlined in light blue and validated targets are indicated in
orange.
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4.4.2 MAGENTA Analyses of miR-137 Target Pathway Gene Sets
The schizophrenia-risk of miR-137 validated and predicted targets was assessed after
targets were classified within canonical pathways according to IPA. Meta gene set
enrichment of variant association analysis using MAGENTA software (Segrè et al.,
2010) revealed several pathway relevant gene sets of miR-137 targets significantly
enriched with schizophrenia-associated variants (Table 4.3). Ephrin receptor signaling,
axonal guidance signaling, and Sertoli cell junction signaling gene sets were significantly
enriched with schizophrenia-associated variants from four out of five gene lists (Table
4.3). The enrichment found for nearly all gene sets specific to these pathways using
higher confidence target lists, strongly suggests that these pathways are indeed enriched
with miR-137 target genes associated with schizophrenia risk. Additionally, synaptic LTP
gene sets from the intersection and validated gene lists, and PKA signaling gene sets
from the full and validated target lists, were enriched in risk genes. The mechanism of
cancer gene set was also significantly enriched, but only from the validated target list.
Overall, analysis of pathway specific gene sets derived from the multiple potential target
lists provided higher confidence for the potential impact of this miRNA within these
pathways.
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Gene Set

Axonal
guidance
signaling

Gene List

Conserved
Context
Intersection
Full
Ephrin
Conserved
receptor
Full
signaling
Context
Intersection
Synaptic
Validated
LTP
Conserved
Mechanisms Validated
of Cancer
PKA
Full
signaling
Validated
Sertoli cell
Intersection
junction
Conserved
signaling
Context
Validated

MAGENTA
Gene Set
Size
19
18
13
40
16
25
12
10
3
13
8

Nominal
GSEA pvalue with
75% cutoff
8.00E-04
5.60E-03
5.80E-03
1.14E-02
4.10E-05
1.00E-03
2.20E-03
3.80E-03
1.69E-02
2.19E-02
2.59E-02

FDR qvalue with
75%
cutoff
4.85E-03
1.99E-02
2.13E-02
2.82E-02
7.00E-04
8.43E-03
1.18E-02
1.36E-02
1.89E-02
3.23E-02
2.75E-02

46
4
11
16
15
4

1.03E-02
4.73E-02
7.40E-03
6.40E-03
1.48E-02
5.24E-02

2.97E-02
4.18E-02
1.84E-02
1.84E-02
2.75E-02
4.88E-02

Table 4.3. Significantly Enriched hsa-miR-137 Pathway-Specific Gene Sets
This table shows the results for the pathway-specific gene sets of Table 4.1 including the number of genes
after conversion to ENTREZ IDs, the gene set enrichment analysis (GSEA) p-value before false discovery
rate (FDR) correction, and the FDR q-value used to determine significance at a threshold of q <0.05. All
gene sets pass the significance threshold. MAGENTA= Meta Gene Set Enrichment of Variant Analysis
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4.4.3 MCIC and NU Replication Cohort Results
MAGENTA analysis of a replication cohort using the MCIC (Gollub et al., 2013) and
NU (Wang et al., 2013) dataset GWAS association p-values revealed one significantly
enriched gene set. The PKA signaling gene set from the validated target list, including
TCF4 and PTGS2 , as well as MAPK1, MAPK3 (experimentally validated indirectly
regulated genes), was significantly enriched with a nominal GSEA p-value of 0.003 and
an FDR q-value of 0.014. Appendix A, Table A.3 shows the top SNPs from this analysis.
As shown in Figure 4.2, the canonical PKA signaling pathway from IPA is enriched with
predicted and validated miR-137 targets, suggesting that this pathway may be involved in
the mechanism of the miRNA in schizophrenia.
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Figure 4.2. miR-137 targets within Protein Kinase A (PKA) Signaling Pathway
This figure depicts the canonical PKA signaling pathway according to Ingenuity Pathway Analysis.
Predicted miR-137 targets based on TargetScan are indicated in pink and validated targets are indicated in
dark blue.

4.5 Discussion
Current research about the recently discovered MIR137 host gene SNP in schizophrenia
suggests that this variant impacts some endophenotypic measures in patients and controls
in a different manner (Lett et al., 2013; Whalley et al., 2012). Therefore, it is likely that
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the interaction of this SNP with additional variants present in patients may increase both
dysregulation by this miRNA and schizophrenia risk. These additional variants may
disrupt targeting efficiency or lead to general disruption of pathway-specific genes,
collectively altering biological processes required for proper brain functioning.
We have previously shown that miR-137 target genes fall within certain biological
pathways more frequently than expected by chance (Wright et al., 2013). Data presented
in this study clearly indicates that the genes in these miR-137 regulated pathways are also
enriched with schizophrenia risk variants, suggesting a potential mechanism for the
association of the MIR137 risk variant. These pathways include Ephrin receptor signaling
targets, axonal guidance signaling targets, synaptic LTP targets, Sertoli cell junction
signaling targets, and PKA signaling targets. As described below, there is supporting
evidence for how each of these may indeed enhance the risk of schizophrenia or impact
the etiology of the disorder.
Ephrin receptor signaling is closely linked to axonal guidance and synaptic LTP,
particularly NMDA dependent plasticity (Filosa et al., 2009). Interactions of the Ephrin
receptors across adjacent neurons or glial cells and neurons help to guide axonal
repulsion (Xu and Henkemeyer, 2012), dendritic spine stability, synaptogenesis (Lin and
Koleske, 2010), and control synapse glutamate concentrations (Filosa et al., 2009), all of
which impact LTP. Schizophrenia imaging genetics studies have found associations
between axonal guidance signaling genes and prediction of fMRI measures of
dorsolateral prefrontal cortex (DLPFC) inefficiency during a working memory task
(Walton et al., 2013). A link between altered LTP and schizophrenia was shown more
directly in a transcranial direct current stimulation (tDCS) study, which found altered
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LTP-like plasticity in patients (Hasan et al., 2013). Additionally, schizophrenia animal
models using NMDAR antagonists, have shown effects on both LTP and behavior
measures demonstrating similar alterations to the cognitive, negative, and positive
symptoms found in humans (Wiescholleck and Manahan-Vaughan, 2013). This suggests
that Ephrin receptor signaling and axonal guidance alterations leading to changes in
NMDA driven synaptic LTP alterations could lead to all three spectra of symptoms
associated with the disorder.
The enrichment of Sertoli cell junction signaling gene sets is compelling as increased risk
of schizophrenia is associated with increased paternal and grandpaternal age (Frans et al.,
2011). Sertoli cells create the supportive niche for the spermatogonial stem cells and
create the blood-testis barrier (Kaur et al., 2014). It is suggested that reduced Sertoli cell
population with age may reduce both germ cell production and quality (Paul and Robaire,
2013). Perhaps alterations in Sertoli cell function via dysregulation by this miRNA could
also reduce germ cell quality of patient fathers and grandfathers.
Finally, the miR-137 validated target PKA signaling gene set (MAPK1, MAPK3, TCF4,
and PTGS2) is of particular interest given that enrichment of schizophrenia-risk
associated variants within these targets was replicated in an independent cohort. PKA
signaling modulates glutamate signaling and responds to dopamine signaling, both highly
implicated in schizophrenia (Sarantis et al., 2009). PKA signaling also appears to play a
critical role in the synergistic interactions between these two neurotransmitter signaling
cascades within the hippocampus and prefrontal cortex through activity of MAPK1 and
MAPK3 (ERK1/2) (Sarantis et al., 2009).
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PKA signaling is also critical for maturation of prefrontal cortex D1 excitability in
adolescence, a region well known for alterations in schizophrenia and a time period of
particular vulnerability (Heng et al., 2011). Inhibition of phosphodiesterase 4 (PDE4), an
enzyme implicated in schizophrenia and involved in the auto-inhibition of PKA
signaling, increases D1 signaling in pyramidal neurons of the prefrontal cortex and
enhanced sensory gating behavior in mice as measured by prepulse inhibition (PPI)
(Juraeva et al., 2014). Interestingly, both schizophrenia and control subjects carrying a
schizophrenia-risk associated variant within the TCF4 gene and mice moderately
overexpressing TCF4, a transcription factor downstream of PKA signaling, (Figure 4.2)
also have disrupted PPI activity ( Brzozka et al., 2010 and Quednow et al., 2014).
Evidence for a role of this molecule in schizophrenia is extensive (Quednow et al., 2014).
TCF4 mRNA expression is increased in human induced pluripotent stem cells (hiPSC)
from schizophrenia patients (Brennand et al., 2011) and increased in postmortem DLPFC
samples of miR-137 risk SNP carriers (Guella et al., 2013).
The remaining PKA gene set molecule, PTGS2, encoding the COX-2 protein, is gaining
attention as a schizophrenia drug target because inhibitors appear to be beneficial in
symptom treatment (Baheti et al., 2013; Müller et al., 2010). PTGS2 mRNA expression is
altered in the prefrontal cortex of patients (Tang et al., 2012). This risk gene is relevant to
the inflammatory basis theories for schizophrenia (Feigenson et al., 2014). As depicted in
Figure 4.2, PTGS2 is responsive in inflammatory processes such as infection, a potential
risk factor for the disorder.
Given the current bioinformatics tools one limitation of this analysis is the lack of
evaluation for the possible creation of new binding sites from polymorphisms in
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unpredicted target genes. Also, the TargetScan algorithm may have missed other true
targets, especially in gene lists where the scope is more constrained. On the other hand,
the algorithm likely predicted false positive interactions, so analysis of the higher
confidence target lists derived from a variety of target prediction scoring lists helps verify
the pathway vulnerabilities. The experimentally validated target list was limited by
current lack of annotation. Our current tools do not allow evaluation of how target SNPs
might impact regulation. Given the heterogeneity and polygenicity of schizophrenia, our
replication sample size was perhaps too small to allow full replication of many of our
results (Purcell et al., 2009). However, the replication of associated variants within the
validated target PKA signaling gene set suggests that other signaling pathways gene set
risk association may be replicated in a larger sample. Moreover, the use of the PGC stage
1 dataset (Ripke et al., 2011) provided a unique opportunity for use of a very large dataset
giving confidence to our findings. Further replication with larger sample sizes will help
validate our results.
Despite these limitations, our analysis of the enrichment of schizophrenia-associated
variants within pathway specific gene sets of potential miR-137 targets suggests that
these pathways are particularly vulnerable to dysregulation by this miRNA.

4.6 Conclusions
Genetic association studies indicate that variants within miRNAs and targets can have
great impact on specific diseases (Abelson, 2005; Wang et al., 2008). These studies often
evaluate variants within one risk gene of interest at a time, and discover alterations in
miRNA binding to that specific target risk gene. However, each miRNA has the capacity
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to target hundreds of targets and impact many different pathways, so determining
possible variants associated with disease that impact miRNA regulation, can be
challenging. Thus studies like this, evaluating many putative and validated targets, are
necessary first steps to guide further research on the impact of specific miRNAs in
diseases.
Many schizophrenia relevant pathways were previously identified to have an
overrepresentation of miR-137 target genes. Our findings of schizophrenia-associated
variants within PKA signaling and other pathways provide a map to guide further
investigation of the role of this miRNA in this illness.
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5.1 Abstract
Background: Evidence suggests that microRNA-137 (miR-137) is involved in the genetic
basis of schizophrenia. Risk variants within the host gene of this miRNA influence
structural and functional brain imaging measures, and miR-137 itself is predicted to
regulate hundreds of genes. We evaluated the influence of a MIR137 risk variant
(rs1625579), in combination with variants in miR-137 regulated genes, TCF4, PTGS2,
MAPK1 and MAPK, on brain imaging measures. These genes were selected based on
previous work showing their relationship with increased risk of schizophrenia.
Methods: We identified the MIR137 risk variant genotype and a genetic risk score based
on genotypes in TCF4, PTGS2, MAPK1 and MAPK3 in 221 Caucasian subjects (89
schizophrenia patients and 132 controls). We evaluated the effects of rs1626679 genotype
with the risk score in a three-way interaction with diagnosis, on the expression of
multivariate gray matter concentration (GMC) patterns.
Results: We found that only schizophrenia subjects homozygous for the MIR137 risk
SNP show a decrease in occipital, parietal, and temporal lobe GMC (including Brodmann
area19, 39, and 40) with increasing miR-137 regulated gene risk score.
Conclusions: Variants within or upstream of MIR137 and regulated genes may in part
influence gray matter measures in the implicated regions in patients with schizophrenia.
These genes are all involved in the PKA signaling pathway suggesting that dysregulation
of the pathway through MIR137 may underlie the gray matter loss seen in the disease.
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5.2 Introduction
Evidence for the role of miR-137 in the genetic basis of schizophrenia is increasingly
accumulating, although the mechanism of association is not known. Interest in the
miRNA began after a single nucleotide polymorphism (SNP), rs1625579, within the host
gene (MIR137) was identified as the top associated SNP in the first large schizophrenia
genome wide association study (GWAS) (Ripke et al., 2011). Four other new variants
were identified in this GWAS within genes now experimentally verified as miR-137
targets (Kwon et al., 2013). A subsequent and larger GWAS identified another SNP near
the miR-137 host gene (Ripke et al., 2013). The largest schizophrenia GWAS to date,
including over 150 000 subjects also identified a SNP, rs1702294, located closely to the
previously identified rs1625579 SNP (Ripke et al., 2014). The consequences of these
SNPs on miR-137 biogenesis has not yet been determined. However, post mortem tissue
analysis suggests that the rs1625579 risk genotype predicts lower miR-137 expression in
the dorsolateral prefrontal cortex (DLPFC) (Guella et al., 2013).
Functional studies indicate that the miRNA is involved in controlling neuronal
proliferation, differentiation, and dendritic arborization (Silber et al., 2008; Smrt et al.,
2010; Sun et al., 2011; Szulwach et al., 2010) all of which are important for proper
neurogenesis, a process implicated in schizophrenia (O’Reilly et al., 2014; Toro and
Deakin, 2007). RNA expression studies suggest that the miRNA regulates expression of
predicted target genes involved in several schizophrenia relevant pathways (Collins et al.,
2014) and confirms regulation of genes involved in neuronal differentiation (Hill et al.,
2014). Bioinformatics studies indicate that a significant number of target genes are
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associated with schizophrenia risk and further predict that the miRNA regulates many
schizophrenia relevant pathways (Wright et al., 2013).
Gray matter loss is well described in schizophrenia (Vita et al., 2012). Imaging genetics
studies seek to determine how genetic factors contribute to specific regions of loss and to
provide insight about how plausible genetic factors may influence the pathophysiology of
the disorder (Hariri et al., 2006). Studies using this approach indicate that the rs1625579
SNP influences a variety of structural and functional measures in patients and controls.
Some effects appear to be common among risk allele carriers regardless of diagnosis,
while other effects appear to be unique to schizophrenia carriers. Findings of common
genotypic effects within homozygous risk allele carriers across diagnostic groups include:
higher activation of the DLPFC during a working memory task (van Erp et al., 2014) and
decreased activation of the posterior right medial frontal gyrus during a sentence
completion task (Whalley et al., 2012). Effects of the genotype specific to schizophrenia
or schizophrenia-at-risk status include: reduced hippocampal volume, increased ventricle
volume, (Lett et al., 2013) increased mid-posterior corpus callosum volume (Patel et al.,
under review), and decreased white matter integrity measures (Kelly et al., 2014; Lett et
al., 2013), as well as, altered activation of the amygdala and pre- and post-central gyrus
during a sentence completion task (Whalley et al., 2012).
Given that miR-137 is known to regulate many schizophrenia risk genes, (Wright et al.,
2013) its effects on schizophrenia-related phenotypes may be modulated by genotypic
variation in its target genes. To our knowledge, no studies have yet evaluated the impact
of the MIR137 risk variant in combination with subsets of target gene variants, on brain
imaging phenotypes. Beginning with a set of miR-137 regulated genes that are also
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associated with schizophrenia risk, we examined the interaction of risk gene genetic
variation, MIR137 risk variants, and schizophrenia disease status on brain measures.
The genes of interest include TCF4, PTGS2, MAPK1 and MAPK3. TCF4 and PTGS2
(which encodes the COX-2 protein) are experimentally validated target genes directly
regulated by this microRNA (Kwon et al., 2013 and Chen et al., 2012). There is
substantial evidence for TCF4 (Quednow et al., 2014) in schizophrenia and more recently
for PTGS2 (Müller et al., 2010; Tang et al., 2012). MAPK1 and MAPK3 are associated
with schizophrenia (Yuan et al., 2010) and are indirectly regulated by miR-137.
Regulation of the activation of the MAPK1 and MAPK3 protein products erk1/2 by miR137 has been consistently demonstrated experimentally (Chen et al., 2011; Liang et al.,
2013; Zhu et al., 2013). These genes group within the PKA signaling pathway according
to Ingenuity Pathway Analysis (IPA) (Ingenuity® Systems, CA, USA,
www.ingenuity.com). Experimental evidence suggests the genes are indeed involved in
this pathway (Taurin et al., 2008; Hino et al., 2005; Tamura et al., 2002; He et al., 2010).
The PKA signaling pathway was shown previously to be overrepresented with predicted
miR-137 target genes (Wright et al., 2013).
We use multivariate analyses (Chen et al., 2014; Turner et al., 2012; Xu et al., 2009) to
avoid region by region or voxel by voxel analyses, to reduce the number of phenotypes
under consideration, while capturing gray matter concentration (GMC) variation
throughout the brain. Here we evaluated the impact of the rs1625579 genotype along
with a genetic risk score combining SNPs within miR-137 regulated genes associated
with schizophrenia-risk and grouping within the PKA pathway (Wright et al., 2014,
unpublished observations) on structural patterns of GMC loss in schizophrenia.
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5.3 Materials and Methods

5.3.1 Subject demographics
Subject imaging and genetic data was derived from the Mind Clinical Imaging
Consortium (MCIC) shared repository (Gollub et al., 2013) and Northwestern University
(NU) datasets (Wang et al., 2013). A total of 221 Caucasian subjects were analyzed from
both datasets. The schizophrenia subject cohort was identified according to the
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for diagnosis of
schizophrenia, schizoaffective disorder or schizophreniform disorder. For MCIC,
controls were excluded based on past or present psychiatric illness including drug abuse
or drug dependence, or use of antidepressants, anti-anxiety medication or sleep aids for
greater than 2 months or within 6 months prior to the MRI scan. All MCIC subjects were
excluded for IQ<70, a history of head injury with prolonged loss of consciousness,
history of skull fracture, or severe/disabling medical conditions. NU subjects were
excluded for drug abuse or dependence, severe medical disorders, head injury history
with loss of consciousness, or diagnosis of mental retardation according to DSM-IV. See
Table 5.1 for subject demographic information and Table 5.2 for patient clinical
information. All subjects provided informed consent and all subject data was collected
according to IRB standards.
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Dataset

MCIC

Controls

90
(61%
male)

42
(55%
male)

60
(75%
male)
150
(67%
male)

Cases

All
Subjects

NU

MCIC/
NU
Merged

Mean
Age

Age
Range

132
(59%
male)

32

14-60

29
(69%
male)

89
(73%
male)

34

17-61

71
(61%
male)

221
(65%
male)

33

21-61

MCIC
Handedness

82 Right
5 Mixed
3 Left
54 Right
4 Mixed
1 Left
1 Unknown
136 Right
9 Mixed
4 Left
1 Unknown

MCIC
Mean
Parent
SES
2.7
range
1-5
2.6
range
1-5

MCIC
Mean
Years of
Education
15.3
range
12-21
13.6
range
7-22

2.65
range
1-5

14.45
range
7-22

Table 5.1. Subject Demographics
Handedness, parent socioeconomic status (SES) and subject years of education was only available for
MCIC subjects. Parent SES was reported by 100 % of controls and 95% of cases. Years of education was
reported by 99% of controls and 93% of cases. Parent SES score was based on the following: 1= Situation
of wealth, education, top-rank social prestige; 2 = College or advanced degree; professional or high-rank
managerial position; 3 = Small businessman, white-collar and skilled worker; high school graduate; 4=
Semi-skilled worker, laborer; education below secondary level; 5 =Unskilled and semi-skilled worker;
elementary education.

Category

Mean
Duration of
Illness (in
years)

MCIC

11.7
range
0.25- 42

NU

NA

Mean
Positive
Symptoms
(SAPS)
4.7
range
0-10
2.1
range
0-10

Mean
Negative
Symptoms
(SANS)
8.0
range
0-15
4.5
range
0-18

Mean
Disorganized
Symptoms
score
(SAPS)
1.7
range
0-6
NA

Mean Chlorpromazine
Equivalence
(4 MCIC subjects were
not medicated with
antipsychotics)
594
range
0-2750
NA

Table 5.2. MCIC Schizophrenia Subject Clinical Information
Table shows available clinical information for the subjects used in this study. For the MCIC subjects
analyzed, 98% of subjects reported duration of illness, 100% reported symptom scores, and 96% reported
medication dosages. For the NU subjects analyzed, 100% of subjects reported positive symptoms scores
and 82 % reported negative symptom scores. SAPS= Scale for the Assessment of Positive Symptoms;
SANS= Scale for the Assessment of Negative Symptoms. Chlorpromazine equivalencies were calculated as
in (Andreasen et al., 2010).
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5.3.2 Genetic data
Genotyping was performed at the Mind Research Network Neurogenetics Core lab using
the Illumina Human Omni-Quad 1M BeadChip for MCIC and the Illumina Human
Omni-Quad 5M chip for NU. Using PLINK, the genotype data from MCIC and NU was
merged after updating SNP locations of MCIC to match that of the more recent NU data.
Quality control was performed before and after merging with the following thresholds:
Hardy Weinberg equilibrium P <10 -6, minor allele frequency < 0.05, missing rate per
SNP < 0.02, missing rate per individual < 0.02. Caucasian subjects were identified using
the Enhancing Neuroimaging Genetics through Meta-Analysis (ENIGMA) multidimensional scaling (MDS) protocol within the imputation protocol
(http://enigma.ini.usc.edu/protocols/genetics-protocols/). Genetic outliers and related
subjects were identified with identity-by-state (IBS) and identity-by-decent (IBD) testing
in PLINK. One individual subject was removed from each pair or group of subjects with
pi-hat values of 0.05 or greater. MCIC subjects were genotyped separately for the
rs1625579 SNP at the Mind Research Network Neurogenetics Core lab using a custom
TaqMan® assay.
5.3.2.1 miR-137 regulated gene genetic risk score
Genetic risk scores were based on variants previously identified to be the top SNPs
associated with schizophrenia risk within miR-137 regulated genes or their respective
regulatory regions, in a gene set enrichment analysis (Wright et al., 2014, unpublished
observation). These SNPs were rs2276195 (TCF4), rs10489401 (PTGS2), rs9610608
(MAPK1) and rs7202714 (MAPK3), see Table 5.3 for SNP information.
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The risk score was calculated across these SNPs for each subject based on the number of
risk alleles (0, 1, or 2) per SNP weighted by its respective odds ratio and summed for all
four SNPs. The risk allele and odds ratio used to create risk scores were derived from the
psychiatric genomics consortium (PGC) recent 2014 GWAS (Ripke et al., 2014),
http://www.med.unc.edu/pgc/downloads. This risk score was rounded to two decimal
places.

Gene

SNP

MIR137

rs1625579

Location

Minor/
Major
Allele

Minor
Allele
frequenc
y in cases

Minor
Allele
frequency
in controls

ChiSquare

P
value

OR for
Minor
Allele

PGC
risk
allele

PGC
2014
odds
ratio

Intronic

G/T

0.163

0.178

0.1705

0.679

0.899

T

1.120

miR-137 Regulated Gene Risk Score SNPs
TCF4

rs2276195

Intronic

T/C

0.163

0.296

10.18

0.001

0.464

T

0.990

PTGS2

rs10489401

Upstream

G/A

0.287

0.398

5.758

0.016

0.608

A

1.005

MAPK1

rs9610608

Upstream

G/A

0.191

0.102

7.037

0.008

2.073

A

0.995

MAPK3

rs7202714

Upstream

T/C

0.393

0.265

8.062

0.004

1.796

T

1.039

Table 5.3. SNP Information
Table shows information for all single nucleotide polymorphisms (SNPs) used in this study. All risk score
SNPs were found to have significantly different minor allele frequencies between cases and controls. OR =
odds ratio; PGC = psychiatric genomics consortium. All SNPs are within110 kb upstream to 40 kb
downstream of each gene’s transcript boundaries.

5.3.3 Imaging data
Structural T1 MRI scans were conducted across 4 sites (University of Minnesota
(UMinn), Massachusetts General Hospital (MGH), the University of Iowa (UIowa), and
the University of New Mexico (UNM)) for the MCIC dataset and one site (Northwestern
University) for the NU dataset. MCIC scans were collected in the coronal orientation
using Siemens (1.5T), GE Signa (1.5T), and Siemans Trio (3) scanners with voxel sizes
of 0.625 X 0.625 X 1.5, 0.664 X 0.664 X 1.6, and 0.625 X 0.625 X 1.5 respectively. NU
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scans were collected in sagittal orientation with a Siemans (1.5T) scanner with 1 X 1 X
1.25 voxel size.
5.3.3.1 Image pre-processing
All T1 Images were co-registered to the same stereotactic space using an affine
transformation, resliced to 2 x 2 x 2 mm, and segmented into cerebrospinal fluid (CSF)
and gray and white matter using the Statistical Parametric Mapping 5 software (SPM5)
unified segmentation method (Ashburner and Friston, 2005). Images were visual
inspected and evaluated for correlation to an averaged image across all subjects. Images
with a correlation value <0.9 to the mean image from all subjects were dropped from
further analysis. Site of scan, gender, and subject age were then regressed out of the gray
matter images to allow further analysis to be more sensitive to group and genotypic
imaging differences. These regressed gray matter images were then smoothed with a full
width half maximum (FWHM) Guassian kernel of 10mm. See (Chen et al., 2014) for
more details on the methods used here.
5.3.3.2 Multivariate SBM image analysis
Independent Component Analysis (ICA) was performed on the pre-processed gray matter
images. This analysis was performed using the SBM module of the GIFT toolbox
(http://mialab.mrn.org/software/gift/index.html). Estimation of the appropriate number of
independent components to capture the variance within the subject image files was
performed using a minimum description length (MDL) method (Li et al., 2007) and was
determined to be 18. We performed a group ICA using the Infomax algorithm and the
ICASSO algorithm 20 times with a bootstrap and random initialization each time. The
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imaging data was decomposed into these 18 GMC components and loading coefficients
or weights respective to the contribution of each structural component to each subject’s
image. These loading coefficients were used to determine group contribution differences
across these GMC components. The spatial maps for the components were all visually
inspected and none were removed as being artifactual.

5.3.4 Imaging genetics statistical analysis
A multiple regression analysis was performed using the loading coefficients for the 18
independent components as dependent variables and diagnosis as the grouping factor to
determine which components captured imaging variance due to diagnostic group. Tests
were deemed significant based on Bonferroni multiple testing correction (p <0.002).
A multivariate analysis with the rs1625579 genotype, diagnosis, and genotyping chip
type included as factors, and the miR-137 regulated gene risk score included as a
covariate was then performed on the loading coefficients of the structural GMC
components showing a diagnosis effect. The main effect of rs1625579, chip type, and risk
score, two-way interactions between genotype and risk score, genotype and diagnosis,
risk score and diagnosis and a three-way interaction between genotype, diagnosis, and
risk score were all considered. Given that only 5 subjects were homozygous for the G
allele, the rs1625579 genotype was analyzed in two groups, those homozygous for the T
allele and those not.
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5.4 Results

5.4.1 Risk score results
The miR-137 regulated gene risk score distribution had a skewness of .610 and kurtosis
of -0.182, suggestive of normality. Mean risk score for patients was 0.025 with a 0.023
standard deviation; for controls, it was 0.012 and 0.022. A two sample t test determined
that the patients’ risk score was significantly greater than the controls’ (t = 4.07, df = 162
p < 0.001, equality of variances not assumed). This remained significant (p < 0.001) after
removing two subjects with extreme single frequency scores. All further analyses were
performed following the removal of these subjects (N = 219). The range of risk scores for
both diagnostic groups was -.02 to 0.08 following this removal.

5.4.2 Imaging results
Three components had loading coefficients significantly associated with diagnostic group
following Bonferroni correction for multiple comparisons (p <0.002). See Appendix B,
Table B.1 and Appendix B, Figure B.1 for the brain regions captured by these
components.

5.4.3 Imaging genetics results
Of the three components significant for diagnosis, one component had a significant a
three-way interaction between the rs1625579 genotype, the miR-137 regulated gene risk
score, and diagnosis (F = 6.3, df = 1, p = 0.013). The main effect of the genotype, risk
score, and the two-way interactions evaluated were not found to be significant. Post hoc
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univariate analysis of the loadings for this component for the two diagnostic groups
separately, accounting for genotyping chip type as a random factor, and evaluating for
two way interactions between risk score and rs1625579 genotype revealed that the
identified three-way interaction in the multivariate analysis was driven by a two-way
interaction in the schizophrenia subjects alone. No significant interaction or main effect
was found in the healthy control group and only the interaction between risk score and
rs1625579 genotype was significant for the schizophrenia subjects (F = 5.98, df = 1, p =
.017). Figure 5.1 and table 5.4 show the areas of GMC variance in this particular
component, with the greatest weightings in the spatial map being in the occipital lobe and
regions of the parietal and temporal lobe.

Figure 5.1. The spatial component showing a genetic and diagnosis interactive effect
This figure shows the regions within the occipital lobe (Brodmann area 19), angular gyrus (Brodmann area
39), supramarginal Gyrus, and the inferior parietal lobule (Brodmann area 40) with greater gray matter
concentration (GMC) in controls than patients. The spatial map is overlaid on a template brain, thresholded
with z scores >|3.5|. The heat map coloring indicates z score intensity, with red indicating findings of GMC
greater in controls and blue indicating areas of GMC greater in patients. White indicates areas with greatest
z scores. The bar on the right indicates z score.
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Finding
Directionality

Area

Positive
CT>SZ

Inferior Occipital
Gyrus/
Inferior Parietal
Lobule
Angular Gyrus

Negative
SZ>CT

L/R
Brodmann
Area
19/40

L/R
volume
(cm3)
0.8/0.6

L/R Max Z score region and
coordinates (x, y, z)

39/39

0.4/0.8

6.3 (-40, -55, 29)/5.9 (44, -55, 27)

Middle Occipital
Gyrus
Occipital Gyrus/
Inferior Temporal
Gyrus
Angular Gyrus/
Inferior Parietal
Lobule
Angular Gyrus

19/NA

1.0/0.0

5.8 (-40, -70, 5)/NA

19/47

0.4/0.3

5.8 (-42, -70, 2)/4.7 (42, -66, 2)

39/40

0.4/1.5

5.3 (-40, -51, 27)/5.7 (40, -41, 37)

39/39

0.3/0.5

4.7 (-40, -55, 32)/5.4 (44, -57, 30)

Inferior Parietal
Lobule,
Supramarginal
Gyrus
Middle Temporal
Gyrus
Fusiform Gyrus

NA/40

0.0/1.3

NA/5.3 (44, -43, 39)

39/39

0.3/0.3

5.1 (-40, -59, 29)/4.6 (46, -57, 23)

19/NA

0.1/0.0

4.3 (-40, -70, -5)/NA

Superior Parietal
Lobule
Calcarine/Lingual
Gyrus
Middle Occipital
Gyrus
Middle Temporal
Gyrus
Cuneus

7/NA

0.1/0.4

3.8 (-34, -65, 51)/4.3 (32, -67, 49)

18/18

0.2/0.1

3.8 (-6, -95, -5)/3.6 (20, -82, -1)

18/NA

0.7/0.0

5.8 (-30, -77, 13)/NA

37/NA

0.8/0.0

5.7 (-44, -56, 5)/NA

23/48

1.0/0.6

4.9 (-18, -55, 25)/4.4 (34, 15, 29)

Middle Frontal
Gyrus
Temporal Gyrus

NA/48

0.0/0.4

NA/4.1 (30, 27, 26)

20/NA

0.3/0.0

4.1 (-46, -23, -24)/NA

Precuneus

23/NA

0.1/0.0

3.9 (-14, -52, 17)/NA

Lingual Gyrus

18/18

0.1/0.1

3.8 (-18, -72, 2)/3.8 (16, -70, 3)

6.4 (-38, -68, 2)/5.2 (36, -41, 37)

Table 5.4. Brain Regions in the Spatial Pattern Showing Genetic and Diagnostic Effects
Table shows the brain regions of gray matter concentration (GMC) variance between patients and controls
for component 11. Positive findings indicate areas where GMC is greater in controls. Negative findings
indicate areas where GMC is greater in patients. Findings are shown for the left (L) and right (R). CT =
Control; SZ= Schizophrenia.

The findings include previously well-known schizophrenia relevant regions including the
angular gyrus (Brodmann area 39), the supramarginal gyrus and the inferior parietal
92

lobule (Brodmann area 40). Appendix B, Figure B.1 depicts the areas of GMC variance
captured by the other two components. Figure 5.2 shows the relationship between the
rs1625579 genotype and the genetic risk for the associated component for both diagnostic
groups. The increased genetic risk by MIR137 genotype and regulated gene risk
genotypes is associated with GMC loss in subjects with schizophrenia but not in controls.

Figure 5.2. Relationship between GMC, diagnosis, rs1625579 genotype, and miR-137 regulated gene
risk score
This figure shows the interaction between the rs1625579 genotype and the miR-137 regulated gene risk
score on structural loading coefficients, and the directionality of the relationship across diagnostic groups.
The solid blue lines indicate the best-fit trend line for subjects with the GG or GT rs1625579 genotype and
the solid green lines indicate that of the TT subjects.
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5.5 Discussion
Our results indicate a schizophrenia-specific interaction of the rs1625579 genotype with
cumulative risk summed across a subset of regulated risk gene SNPs. The interactive
effect of this genotype with the miR-137 regulated risk score is reduced GMC within the
occipital, parietal, and temporal lobe. Within patients with schizophrenia, those with two
risk alleles (TT) showed decreasing GMC in these regions with increasing genetic risk
score, while those with only a single or no risk allele did not. This pattern was not present
in healthy controls, and if anything was reversed.
This suggests that within schizophrenia, the rs1625579 MIR137 SNP in conjunction with
specific genotypes in the PKA pathway may cause altered regulation of the genes within
our risk score and lead to decreased GMC within Brodmann area 19 of the occipital lobe,
Brodmann area 39 of the angular gyrus, and Brodmann area 40 of the supramarginal
gyrus and inferior parietal lobule. These regions have all previously been implicated in
schizophrenia and are associated with exploratory eye movement dysfunction (Qiu et al.,
2011), theory of mind or self-sensing deficits (Guo et al., 2014), hallucinations (CurcicBlake et al., 2013; Chen et al., 2013; Diederen et al., 2012; Sommer et al., 2012),
adaptive control deficits (Becerril and Barch, 2013), and attention deficits (Thimm et al.,
2011; Huang et al., 2010). This raises promising possibilities that these genetic variations
within people with schizophrenia could be related to GMC and functional loss within
these networks, leading to previously unexplained variation in their clinical symptoms
and capabilities.
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Interestingly, a risk genotype for a variant within another miR-137 experimentally
validated target gene, CACNA1C, was associated with reduced activity in Brodmann area
40 during orientation of attention in an fMRI study (Thimm et al., 2011). Gray-matter
volume decrease of the supramarginal gyrus was also associated with poor cognitive test
scores in unaffected relatives of schizophrenia patients, further suggesting genetic
liability of alterations in this region (Bhojraj et al., 2011). The 22q.11.2 deletion, one of
the highest known risk factors for schizophrenia is associated with altered miRNA
biogenesis (Sellier et al., 2014) and cortical morphological reduction of this region,
(Kates et al., 2011). The effect of the MIR137 risk SNPs on the biogenesis of the miRNA
has not been determined, but postmortem tissue analysis (Guella et al., 2013) suggests
that the biogenesis may be disrupted with the rs1625579 risk genotype. Therefore, other
findings implicating this region with reduced miRNA biogenesis may be in part due to a
reduction of miR-137.
Very few studies have evaluted the role of PKA signaling on GMC in the brain regions
implicated here. However, evidence suggests that this signaling pathway (Funk et al.,
2012) and each of the investigated genes within it are associated with schizophrenia
overall (Müller et al., 2010; Quednow et al., 2014; Yuan et al., 2010). Further research is
required to determine the exact mechanism of the association presented in this study, to
determine the replicability of these findings, and to determine if these genetic factors also
influence exploratory eye movement, self-sensing, hallucinations, adaptive control, or
attention characteristics. Our analysis is a first step into determining the combined effect
of MIR137 variants with miR-137 regulated gene variants and our results suggest a key
structural and functional region is affected by rs1625579 vulnerability.
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6. General Discussion
6.1 Findings and significance
The goals of this project were: 1) to identify and characterize all predicted and
experimentally validated target genes; 2) to determine enrichment of schizophrenia
associated variants within pathway relevant miR-137 target gene sets; and 3) to evaluate
the effect of the MIR137 schizophrenia risk SNP, rs1625579, in addition to target gene
polymorphisms on structural gray matter.
The results of this project increase our understanding of the influence of miR-137 in
schizophrenia in three ways:
1) We identify that the putative and confirmed targets of this miRNA fall into pathways
relevant for schizophrenia development.
2) We identify that many of these same putative and confirmed targets are associated
with schizophrenia risk.
3) We determine that a particular gene set of target genes affects gray matter in brain
regions previously identified to mediate schizophrenia phenotypes.
At the onset of this project, the first genetic association study linking rs1625579 with
schizophrenia included an evaluation of the enrichment of associated SNPs within a
limited number of predicted target genes and found a significant enrichment (Ripke et al.,
2011). This same research group later replicated this finding using a joint set enrichment
method (Ripke et al., 2013). At that time, no other studies had investigated the targets of
this miRNA or their possible role in schizophrenia. Given that miRNAs can regulate
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hundreds of target genes (Bartel, 2009) and thus a great number of biological pathways
and functions, it is highly probable that the mechanism for the involvement of miR-137
in schizophrenia would involve target genes that play some critical role in schizophrenia
relevant pathways.
With our first goal, we identified many target genes to be associated with schizophrenia
and we determined that these target genes have unique temporal expression profiles, with
peak expression levels during developmentally critical time-periods. miR-137 target
genes were found to be overrepresented in several schizophrenia relevant pathways. This
was the first evaluation of miR-137 target genes in a pathway approach and demonstrated
that pathways involved in neuronal development and plasticity, such as axonal guidance
signaling, Ephrin receptor signaling, and long-term potentiation, were indeed enriched
with targets of the miRNA. Additionally we identified other miR-137 target enriched
pathways that maybe more distantly impactful, such as Sertoli cell junction signaling.
Since then, two recently published studies evaluated enrichment of dysregulated genes
within pathways, following over-expression and inhibition of miR-137. Their results
identified an overrepresentation of dysregulated genes within pathways of MHC genes,
synapse formation, calcium channel signaling (Collins et al., 2014), and neuronal
differentiation (Hill et al., 2014). All of these pathways have been previously associated
with schizophrenia (Mukherjee et al., 2014; Yang et al., 2014; Berridge, 2013; O’Reilly
et al., 2014 and Toro and Deakin, 2007) and brain development (Durand et al., 1996; Sun
et al., 2009; Wu et al., 2011; and Rosenberg and Spitzer et al., 2011). These studies
further suggest that the miRNA may contribute to developmental regulation of the
nervous system. Therefore, consistent with the neurodevelopmental basis theory for
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schizophrenia, (Gupta and Kulhara, 2010), the miRNA may contribute to schizophrenia
risk by altering regulation of the nervous system processes during development.
Our next goal was to evaluate the schizophrenia risk contribution of target genes within
our previously identified target enriched pathways. We identified several target gene sets
specific to neuronal development and plasticity pathways among others that had
significantly more schizophrenia-associated variants than 10,000 random gene sets of the
same size. This included target gene sets from the following pathways: Ephrin receptor
signaling, axonal guidance signaling, synaptic LTP, and Sertoli cell junction signaling,
and PKA signaling. We successfully replicated significant enrichment of associated
variants within a regulated gene set of genes involved in PKA signaling in a separate
cohort. This analysis was the first evaluation of schizophrenia risk contribution of miR137 targets in a pathway specific manner. Additionally our study was the first to analyze
risk contribution of experimentally validated targets rather than putative targets alone.
Our findings suggest that the miRNA may contribute to schizophrenia risk by disrupting
regulation of targets within these pathways.
The final goal of our studies was to determine if variants of target genes may in concert
with the miR-137 host gene (MIR-137) variant alter gray matter measures. We chose to
focus our investigation on the polymorphisms within the target genes and downstream
regulated genes of the PKA signaling gene set associated with schizophrenia risk in the
second aim, as this schizophrenia association for this gene set was replicated in a separate
cohort. This was the first analysis of the influence of the MIR-137 risk SNP rs1625579
genotype in combination with miR-137 regulated gene SNP genotypes on brain imaging
measures. A risk score was used to investigate the contribution of regulated gene variants
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on gray matter concentration. Gray matter concentration variance among all subjects was
determined using Source Based Morphometry, a multivariate approach using independent
component analysis (Ashburner and Friston, 2005). This produces loadings for each
subject that represent weights for each subject’s contribution to each component (in this
case, brain regions of gray matter concentration) found to vary within the subjects
analyzed. Three components were found to capture gray matter concentration variance
between patients and controls. miR-137 regulated gene risk score was evaluated with the
rs1625579 genotype in a multivariate analysis with the subject loadings for these imaging
components to determine if these genotypes would affect gray matter concentration in the
areas found to be different in patients and controls. A significant three-way interaction
was identified for the rs1625579 genotype, the risk score of miR-137 regulated genes,
and diagnosis for one component. This component includes schizophrenia relevant areas
such as Brodmann area 39 and 40 of the angular gyrus, supramarginal gyrus, and inferior
parietal lobule and Brodmann area 19 of the occipital lobe which are known to be
involved in several schizophrenia phenotypes including: exploratory eye movement
alterations (Qiu et al., 2011), hallucinations (Curcic-Blake et al., 2013), and deficits of
attention (Thimm et al., 2011; Huang et al., 2010), self-sensing (Guo et al., 2014) , and
adaptive control (Becerril and Barch, 2013). Therefore, mir-137 and these regulated
genes involved in the PKA signaling pathway may genetically underlie these associated
phenotypes. Suggestive that this miRNA may indeed impact these functions, attention
orientation deficits and reduced activity within Brodmann area 40 was found in subjects
carrying a risk genotype within another experimentally validated miR-137 target,
CACNA1C (Thimm et al., 2011). Furthermore, Cummings et al., 2012 found that patients
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homozygous for the rs1625579 risk T allele performed worse in attention related tasks.
Our imaging genetics findings in this analysis can help guide further studies to determine
the influence of this miRNA on the phenotypes associated with schizophrenia. This may
one day lead to more specific drug targets for particular symptom subtypes or lead to
discovery of functional and structural biomarkers to assist in diagnosis.
Overall, our analyses suggest that miR-137 regulates schizophrenia associated target
genes involved in neuronal development and plasticity pathways relevant to
schizophrenia. Many of these target genes have variants associated with schizophrenia
that may disrupt regulation by the miRNA. A conglomerate of target gene
polymorphisms disrupting miR-137 regulation within a pathway may lead to altered
functioning of the pathway. For pathways involved in neuronal development, this may
alter development of the brain, such as gray matter structure, and lead to a predisposition
for the development of schizophrenia. Alterations in pathways involved in plasticity may
also lead to altered development, as well as continued alterations of brain functioning
which may contribute the ongoing symptom expression associated with the disorder.
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Figure 6.1 Model of the mechanism for the influence of MIR137, miR-137, and miR-137 regulated
genes in schizophrenia
This figure shows the potential effects of the MIR137 schizophrenia-risk variants in conjunction with target
gene variants on the functional activity of miR-137 in schizophrenia. MIR137 risk variants may disrupt
miR-137 biogenesis by altering the splicing of the pri-miRNA from the host gene. This may lead to
decreased production of premature and ultimately mature miR-137. A reduction in the mature miR-137 in
combination with target gene alterations that further reduce the regulatory activity of the miRNA, may lead
to disrupted activity of pathways highly enriched with miR-137 target genes. This may ultimately lead to
altered developmental and plasticity related processes, which may either increase schizophrenia risk or
potentiate alterations associated with the disorder itself.
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Figure 6.1 shows a suggested model for how the miR-137 host gene (MIR137) variants
(specifically, rs1625579 or rs1702294), miR-137 and its targets may be involved with the
pathophysiology of schizophrenia. Depicted in the top half of the model, variants within
the host gene may alter the biogenesis of miR-137. miR-137 is coded within an exon of
long noncoding gene MIR-137. The mechanisms involved in the excision of these
unusual pre-miRNAs derived from noncoding sequences is not well known. SNPs can
alter Drosha and Dicer processing, by decreasing efficiency due to altered immature
miRNA sequence stability or may alter the cleavage sites leading to shifted or altered
seed sequences. Processing by these enzymes appears to be more structure-based than
sequence-based, as variants outside of the pre-miRNA and mature miRNA sequences can
alter processing (Sun et al., 2009). Therefore, for unusual miRNAs like miR-137, variants
downstream or upstream of the pri-miRNA sequence may disrupt the excision of the primiRNA from their noncoding host genes. Like other processing influential SNPs, the
rs1625579 variant, or other nearby schizophrenia associated variants such as rs1702294,
could shift the excision or reduce excision efficiency. Given that postmortem tissue
analysis suggests that the rs1622579 genotype is associated with reduced mature miRNA
expression (Guella et al., 2013), it seems probable that these SNPs may reduce processing
efficiency. These SNPs may reduce the stability of the host gene transcript, leading to
reduced production of the pri-miRNA, and subsequently reduced production of the
mature miRNA. Alternatively, these SNPs may shift excision to produce a less stable primiRNA sequence, leading to reduced pre-miRNA and mature miRNA production.
Many of the imaging findings suggest that the rs1622579 risk genotype influences
structural and functional MRI measures in schizophrenia patients in a distinct manner
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than healthy controls. In agreement with the polygenic basis of the illness (Purcell et al.,
2009), this suggests that there are additional variants within these patients responsible for
these disease specific MRI measure alterations. These additional variants may be SNPs
within target genes that disrupt targeting by the miRNA. The effect of these SNPs are
illustrated in the bottom half of the model. These SNPs may disrupt target gene binding
affinity and availability for the miRNA. Thus, an overall reduction of miR-137
production coupled with reduced targeting may lead to substantially reduced regulation
of target genes. This may then alter functioning of pathways highly concentrated with
targets and lead to alterations in brain development or functioning that may ultimately
lead to the development of schizophrenia or progression of the disorder.

6.2 Limitations
There are several limitations associated with the analyses discussed in this dissertation.
Our pathway analysis with IPA is limited, in that pathway definition is dependent on the
software annotation used for analysis. It is not obvious how broadly or narrowly inclusive
a pathway should be defined. Regardless it is clear that these molecules interact with one
another to provide a biological function and thus variants within several molecules can be
disruptive, but the function disrupted may be less clear. However, this still provides a
closer estimate biologically of how miR-137 target gene regulation may underlie
schizophrenia. Many of the studies included putative target genes predicted with
TargetScan. This prediction algorithm predicts targets based on conservation of seed site
sequence, miRNA seed and mRNA sequence complementarity, nearby sequence
complementarity, and binding stability. However, it is suggested that as many as 30% of
predicted targets by such algorithms are false positives (Zheng et al., 2013). To account
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for these false positives, experimentally validated targets and predicted targets restricted
by prediction scores were also included in evaluations. Unfortunately, annotation of
validated miR-137 targets remains very limited at this time and largely includes genes
involved in cancer. Additionally the current validation experiments do not determine coexpression of miRNAs and their respective targets in the same place and time. However,
these targets are still more likely to be true target genes than other predicted targets.
In our evaluation of schizophrenia association of polymorphisms within target gene sets,
we could not assess the possibility that polymorphisms may create new miR-137 targets.
However, some falsely predicted targets might make up a population of low binding
predicted targets that may become a true target with the right polymorphism.
Additionally, polymorphisms can be falsely associated in a GWAS. However, the data set
used was so large (over 21,000 subjects) that this is less likely. (Shen and Carlborg,
2013). Our replication analysis in a separate cohort also provide more confidence for our
results; however, only one target gene set demonstrated to be enriched with associated
variants in the replication cohort. Our replication cohort was rather small, and we may
not have had statistical power enough to allow for replication of other target gene set
associations.
The effect of these identified polymorphisms within MIR137 and miR-137 target genes
on regulation by the miRNA was not evaluated in these studies. Annotation of the effect
of these SNPs is currently very limited. However, such annotations should be more
available in the future. Further studies could also bioinformatically assess the effect of
each of these target gene polymorphisms as well as the influence of the MIR137 variants
on miR-137 biogenesis and function.
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Our imaging genetics cohort proved to be large enough to evaluate the influence of
variants of miR-137 regulated genes on gray matter concentration measures; however, we
did not have imaging and genetic data for additional subjects to perform a replication
analysis for the third aim findings. Although we found a significant interactive effect of
diagnosis, the rs1625579 genotype, and the miR-137 regulated gene based risk score on
gray matter concentration within schizophrenia relevant brain regions, our methods could
not evaluate how these genetic factors may specifically interact. More research is
necessary to determine if these polymorphisms affect these genes and regulation by the
miRNA in schizophrenia. Further studies will also be necessary to determine this
significance of these variants on the functional activity of these and other regions. We
can also not rule out that some of the GMC findings may be due to medication effects
rather than disease status. However, regardless if medication is more responsible for the
GMC losses found instead of schizophrenia itself, these genetic variants may still
influence GMC medication effects. Thus, these genetic variants may be important in
determining patient drug response. Additionally, our studies did not evaluate the
influence of the interaction between age and diagnosis on gray matter. However,
additional studies in our lab suggest this interaction does not cause significant gray matter
alterations. Finally, many studies will be necessary to evaluate the influence of other
miR-137 regulated genes not examined in this analysis on imaging measures.

6.3 Future directions
The studies presented here provide an estimate for how this miRNA and its target genes
may be involved in schizophrenia. As miR-137 can regulate many targets and pathways,
our studies reduce the dimensions of further research trajectories. Therefore, our findings
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provide a guide for further research in this area, so that it may be more effective and
efficient.
The effect of the MIR137 SNP rs1625579 on miR-137 expression and function is not well
studied and no studies have analyzed the effect of the very recently identified MIR137
SNP rs1702294. Guella et al., 2013 found reduced miR-137 expression in the DLPFC of
rs1625579 risk allele homozygotes. This was a limited study however, that used only 10
control subject samples and 7 schizophrenia subject samples. Further research using
postmortem tissue and cell culture assays can help determine the effect of this genotype
and the rs1702294 genotype on miR-137 expression. RNA sequencing of postmortem
tissue from patients and controls can determine if the risk genotypes are associated with a
reduction or alteration in the premature and mature forms of the miRNA. Comparison of
RNA sequencing or Northern Blot analysis following HEK293 cells, which are known
not to express miR-137(Kozlowska et al., 2013), transduced with lentivirus vectors
containing the host gene MIR137 with the alleles of the associated variants (rs1625579
and rs1702294) can assist in determining if the MIR137 variants alter biogenesis of the
pri-, pre-, or mature miRNA.
As stated in the limitations, the current studies did not evaluate the effect of target gene
variants on miR-137 regulation. Bioinformatics studies could first determine which
variants are more likely to disrupt pathway functioning and miR-137 regulation. This
could be done by determining targets that contain non-synonymous SNPs, SNPs within
promoter regions, SNPs within the 3’UTR, or the miR-137 seed site sequence. Nonsynonymous SNPs, SNPs that alter subsequent protein amino acid sequence, may lead to
alterations in protein function, which could disrupt pathway functioning. SNPs in
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promoter regions may alter transcription of target genes; this coupled with disrupted miR137 regulation may lead to further altered expression of gene products and effect
pathways containing such genes. SNPs within 3’ UTRs or seed site sequences may alter
miR-137 regulation by altering binding or binding availability of the miRNA due to
secondary structure alterations (Abelson, 2005; Wang et al., 2008).
In vitro studies can determine if these non-synonymous SNPs alter the function of
implicated targets and the function of other downstream pathway molecules. Northern
blot analysis can help determine if SNPs within promoter regions leads to altered gene
expression of targets. Luciferase studies using plasmids expressing target 3’UTRs and
overexpression of the miR-137 primary sequence could confirm if s 3’ UTR and seed site
SNPs alter regulation by the miRNA. Structural and functional MRI analyses can help
further determine the consequences of polymorphisms believed to effect target and
pathway regulation by the miRNA.
The studies described in this dissertation suggest that the PKA signaling pathway may be
involved in the mechanistic role of miR-137 in schizophrenia. Evaluation of the
regulation and function of the target genes within this pathway, with the mentioned
methods above are an obvious potential first next step. Our imaging genetics findings
suggest that variants of miR-137 regulated genes within this pathway affect structure
within brain regions known to be involved in attention, hallucination, self-sensing, and
adaptive control. Functional MRI studies could help determine if carriers of the identified
risk SNPs also have altered activity in these areas and measures of these phenotypes. One
simple first step would be to evaluate if positive symptom score is higher in subjects with
the rs1625579 risk allele and higher miR-137 regulated gene risk score.
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No studies have evaluated the influence of variants within miR-137 regulated genes and
MIR137 on symptom scores and schizophrenia relevant phenotype measures. Limited
studies have evaluated the effect of the rs1625579 genotype alone. Green et al., 2012
found subjects carrying the protective G allele, and who had more severe negative
symptoms scores performed worse at cognitive tasks. Perhaps in these patients additional
variants responsible for the worsened negative symptoms may also worsen cognitive
deficits with a slightly different genetic basis. In support of our findings, Cummings et
al., 2012 found that the T allele was associated with attention deficits, however, these
subjects also scored lower for positive symptoms. This suggests that these particular
variants may affect the other implicated schizophrenia associated phenotypes rather than
hallucination. However, it is possible that this is again due to a genetic variant and
medication interaction. Perhaps risk TT carriers are more likely to be responsive to
treatment of positive symptoms regardless of baseline status. Longitudinal studies
evaluating prodromal subjects, such as that of Addington et al., 2007, may help to
determine the influence of these genotypes on treatment response. Such studies can also
assist in determining if our GMC findings are due to disease status rather than medication
effects.
While we are still far from determining the impact of this miRNA in schizophrenia, the
use of a pathway approach with the methods described above may streamline our
investigation and our results so far suggest avenues of further research. Determination of
pathways dysregulated by miR-137 may ultimately provide alterative drug target
candidates for future treatments.
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6.4 Conclusions
Evidence of miRNA impact in psychiatric illness is ever growing. Substantial evidence
for miR-137 involvement in schizophrenia is apparent. However, it is unclear how the
miRNA influences the disorder. The studies presented here provide the first thorough
investigation of miR-137 targets and the consequences of their possible dysregulation in
the disorder. The results of these studies suggest that the miRNA may affect pathways
involved in neuronal development and plasticity through the regulation of target genes.
These pathways may be dysregulated in schizophrenia and may lead to altered gray
matter concentration, which may influence important phenotypes associated with the
disorder, such as hallucinations, attention and adaptive control deficits and exploratory
eye movement deficits. These alterations may be part of the progression of schizophrenia
development itself or may predispose individuals to development of the disorder. Further
research is necessary to elucidate if targets are indeed dysregulated by the miRNA in
schizophrenia and the consequences of such dysregulation. Overall, these studies provide
a guide for future research to clarify the role of this miRNA and its targets in this
devastating disorder. Determination of the mechanism of this miRNA involvement may
ultimately inspire novel treatments that may improve patient wellbeing.
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Appendix A: Supplemental Data for Meta Gene Set Enrichment
Analyses Link miR-137-regulated Pathways with Schizophrenia Risk
Article

Target List
Name

Criteria

TargetScan
Predicted
Target
Genes

Validated
and
Predicted
Overlap

Full List

None

1144

Conserved
List
Context List

Pct ≥ 0.9

Intersection
list
Validated
List

Relevance

26

Total
Target
Genes
Including
Validated
targets
1154

537

13

560

Conserved

Context ≤ 0.12

577

16

597

Pct ≥ 0.9 and
Context ≤ 0.12
Experimental
Validation
Study

283

8

311

None

None

36

Less
Conserved,
Strong Binding
High
Confidence
Conserved
Highest
Confidence,
Least Inclusive

Most Inclusive

Table A.1. Curated target gene lists of hsa-miR-137
This table depicts the scoring criteria for each curated list, the number of predicted targets for each gene
list, the number of validated targets that were also predicted, and the total number of targets in the final list
listed by gene symbols. The relevance column indicates how each gene list contributed to the analysis. Pct
= probability of conserved targeting. For further details see Methods section.

112

Dataset

PGC

MCIC

NU

MCIC and NU
Merged

Controls 12,462 (49% male)

97 (59% male)

44 (52% male)

141 (57% male)

Cases

9,394 (66% male)

73 (75% male)

30 (67% male)

103 (73% male)

Total
Subjects

21,856 (56% male)

170 (66% male)

74 (58% male)

244 (64% male)

Table A.2. Dataset demographics
This table shows the demographic information of each dataset used in this analysis. PGC = Psychiatric
Genomics Consortium; MCIC = Mind Clinical Imaging Consortium; and NU = Northwestern University.
All subjects were Caucasian. Subjects from MCIC and NU and nearly all PGC subjects were diagnosed
based on the DSM-IV criteria. Only one cohort of subjects within the PGC was diagnosed according to
ICD-10. Case subjects included those diagnosed with schizophrenia, schizophreniform disorder, or
schizoaffective disorder. Controls were excluded with a past history of psychiatric illness or substance
abuse. DSM = Diagnostic and Statistical Manual of Mental Disorders; ICD = International Classification of
Diseases.
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Gene

Top SNP

Minor
/Major
Allele

Minor
Allele
frequency
in controls
0.3901

ChiSquare

G/A

Minor
Allele
frequency
in cases
0.2864

PTGS2

rs10489401

MAPK3

P
value

OR for
Minor
Allele

5.651

0.017

0.6276

rs7202714

T/C

0.3627

0.273

4.447

0.034

1.515

TCF4

rs2276195

T/C

0.165

0.2908

10.39

0.001

0.4821

MAPK1

rs9610608

G/A

0.1796

0.09574

7.348

0.0067

2.068

Table A.3. Significant association of SNPs in validated PKA signaling target genes with
schizophrenia in the replication cohort
This table shows the top SNPs from the validated PKA signaling target gene set for the merged MCIC and
NU data. All SNPs have significantly different frequencies between cases and controls. Analyses were
performed in PLINK. OR = Odds Ratio
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Appendix B: Supplemental Data for Polymorphisms in MIR137 and
microRNA-137 regulated genes influence gray matter structure in
schizophrenia Article

Component
Number

1

F

61

df

1

P
value

<.001

Effect
Size
(Cohen's
d)

1.04

Loadings
Directionality

CT>SZ

L/R
Volume
(cm3)

Brodmann
Area

2.2/2.4

38

3.2/2.8

38

1.6/2.4

32,10

1.0/1.0

NA

1.0/0

19

Angular
Gyrus/Inferior
Parietal Lobule

0.4/1.5

39,40

Inferior Parietal
Lobule/Supramarginal
Gyrus

0.0/1.3

40

Calcarine
Superior Occiptal
Gyrus
Middle Temporal
Gyrus

2.9/4.0

17

3.7/3.5

17

0.2/2.2

21,39

Sub-Gyral

0.6/1.2

NA

Brain Region Label
(Positive/Negative)
Superior Temporal
Pole
Superior Temporal
Pole
Medial Frontal Gyrus
Superior Temporal
Gyrus
Middle Occipital
Gyrus

11

6

11

12

1

1

0.001

0.001

0.62

0.48

CT>SZ

CT>SZ

Table B.1 Imaging Components Showing Differences in GMC between Patients and Controls
This table shows the major findings, significance value and effect size for the three components that
captured GMC differences between patients and controls. CT= Control; SZ=Schizophrenia.
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Figure B.1 Regions of GMC Variance between Patients and Controls for Component 1 and 6
This figure shows the regions of GMC variance between cases and controls for the components found to
significantly capture diagnostic variance but not genotypic variance. The spatial map is overlaid on a
template brain, thresholded with z scores >|3.5|. The heat map coloring indicates z score intensity, with red
indicating findings of GMC greater in controls and blue indicating areas of GMC greater in patients. White
indicates areas with greatest z scores. The bar on the right indicates z score.
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Abbreviations Used
ADAR

Adenosine Deaminase Acting on RNA

Ago 2

Argonaute 2

ASD

Autism Spectrum Disorders

CNV(s)

Copy Number Variation(s)

CSF

Cerebrospinal Fluid

CT

Control Subjects

DCGR8

DiGeorge Syndrome Critical Region Gene 8

DLPFC

Dorsolateral Prefrontal Cortex

DSM-IV

Diagnostic and Statistical Manual of Mental Disorders-IV

ENIGMA

Enhancing Neuroimaging Genetics through Meta-Analysis

FDR

False Discovery Rate

fMRI

Functional Magnetic Resonance Imaging

FWHM

Full Width Half Maximum

GMC

Gray Matter Concentration

GNRH

Gonadotropin-releasing Hormone

GSEA

Gene Set Enrichment Analysis

GWAS

Genome Wide Association Study

HGF

Hepatocyte Growth Factor

HITS-CLIP

High-Throughput Sequencing of RNA Isolated by Crosslinking
Immunopercipitation

HTT

Huntington’s Associated Protein Huntingtin

IBD

Identity-By-Decent

IBS

Identity-By-State

ICA

Independent Component Analysis
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IPA

Ingenuity Pathway Analysis

L

Left Side

LIBD

Lieber Institute for Brain Development

LTP

Long-term Potentiation

MAGENTA

Meta Gene Set Enrichment of Variant Analysis Software Program

MCIC

Mind Clinical Imaging Consortium

MDL

Minimum Description Length

MDS

Multi-dimensional Scaling

MGH

Massachusetts General Hospital

MHC

Major Histocompatibility Complex

miR-137

microRNA 137

MIR137

microRNA 137 host gene

miRISC

microRNA Induced Silencing Complex

miRNA

microRNA

NIMH

National Institute of Mental Health

NMJ

Neuromuscular Junction

NS

Nervous System

NU

Northwestern University

OR

Odds Ratio

PACT

Protein Activator of the Interferon Induced Protein Kinase

Pct

Probability of Conserved Targeting

PGC

Psychiatric Genomics Consortium or Psychiatric Genome-Wide
Association Study Consortium

PKA

Protein Kinase A

PPI

Prepulse Inhibition

R

Right Side
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SANS

Scale for the Assessment of Negative Symptoms

SAPS

Scale for the Assessment of Positive Symptoms

SES

Socioeconomic Status

SIRP

Sternberg Item Recognition Paradigm Working Memory Task

SNP

Single Nucleotide Polymorphism

SPM5

Statistical Parametric Mapping 5 Software

SZ

Schizophrenia Subjects

SZGR

Schizophrenia Gene Resource

tDCS

Transcranial Direct Current Stimulation

TRBP

Trans-Activation Response RNA Binding Protein

UIowa

University of Iowa

UMinn

University of Minnesota

UNM

University of New Mexico
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